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The goal of this dissertation was to investigate the role of µ-opioid receptors in 
the mechanism of ethanol-stimulated dopamine release in the nucleus 
accumbens shell (NAcS) of rats. The underlying hypothesis is that blockade of 
the µ-opioid receptors leads to an attenuation of ethanol-stimulated mesolimbic 
dopamine release. We prepared ethanol-naïve male Long Evans rats (n = 95) for
intravenous (i.v.) drug administration and in vivo microdialysis (in awake, freely 
moving animals), and analyzed our samples using HPLC and GC for dopamine 
and ethanol detection, respectively. In one set of experiments, we looked at the 
effects of naltrexone, a non-selective opioid antagonist, on ethanol-stimulated 
mesolimbic dopamine release. First of all, we checked to see if naltrexone 
affected basal dopamine levels in the NAcS. Thereafter, we looked for a dose of 
naltrexone (i.v.) that was effective in suppressing the release of dopamine in the 
NAcS evoked by morphine (1 mg/kg, i.v.). Subsequently, we checked to see if 
doses of naltrexone that inhibited morphine-evoked dopamine were also effective
vii
in attenuating dopamine release due to ethanol (1g/kg, 10% w/v, i.v.). To do this, 
we pretreated rats with naltrexone doses, followed 20 min later by morphine, 
ethanol or saline (all drugs were administered i.v.). In another set of experiments, 
we looked at the effect of β-funaltrexamine, a selective µ-opioid antagonist, on 
ethanol-stimulated dopamine release in the NAcS. Similarly to the previous set of 
experiments, we looked for a dose of β-funaltrexamine (s.c.) that was effective in 
suppressing the release of dopamine the NAcS evoked by morphine (1 mg/kg, 
i.v.), and checked to see if this dose of β-funaltrexamine was also effective in 
attenuating ethanol-stimulated dopamine release in the NAcS. For the β-
funaltrexamine experiments, rats were pretreated with β-funaltrexamine (s.c.) 20-
25 h before i.v. infusions of saline, morphine and ethanol.
Morphine increased dopamine release in the NAcS. Naltrexone and β-
funaltrexamine significantly attenuated morphine-evoked dopamine release. 
Also, ethanol increased dopamine release in the NAcS. Naltrexone and β-
funaltrexamine, at doses effective in attenuating morphine-evoked dopamine 
release, suppressed the prolongation, but not the initiation of dopamine release
in the NAcS due to ethanol. Naltrexone and β-funaltrexamine did not affect the 
peak concentration and clearance of ethanol in the brain. The conclusion of this 
study is that the µ-opioid receptors are involved in a delayed component of 
ethanol-stimulated dopamine release in the NAcS in ethanol-naïve rats. This is 
the first study to show that the ethanol-stimulated dopamine response consists of 
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Chapter 1. General Introduction
ETHANOL ABUSE AND DEPENDENCE
Consequences of Ethanol Abuse
It is not unusual to see a documentary or an exposition about alcohol abuse and 
its consequences on society. We have seen messages in the media ranging from 
‘don’t drink and drive’ and ‘friends don’t let friends drive drunk’ to ‘drink, drive, go 
to jail’ and ‘drunk driving is a crime’. Excessive alcohol consumption is the third 
leading preventable cause of death in the United States (U.S.) (Mokdad et al., 
2000). Alcohol is involved in nearly 
one-third of all traffic-related deaths in 
the U.S (NHTSA, 2008) (see Table 
1.1). Apart from traffic-related 
fatalities, alcohol has been linked, in 
some cases, to domestic violence 
(Brewer and Swahn, 2005). The 
consequences of alcohol abuse to 
every individual and to society as a 
whole cannot be overemphasized.
But what is alcohol? Alcohol, in this 
case, is ethyl alcohol or ethanol. 
Ethanol usually refers to grain alcohol, 
and is a colorless, volatile liquid with a






2000 41,945 13,324 (31.8%)
2001 42,196 13,290 (31.5%)
2002 43,005 13,472 (31.3%)
2003 42,884 13,096 (30.5%)
2004 42,836 13,099 (30.6%)
2005 43,510 13,582 (31.2%)
2006 42,708 13,491 (31.6%)
2007 41,059 12,998 (31.7%)
Table 1.1. The percentage of alcohol-
related driving fatalities in the United 
States from 2000-2007. Adapted from 
NHTSA Traffic Safety Facts - Research 
Note (2008). NHTSA = National Highway 
Traffic Safety Administration.
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fermentation of sugars. The drinking of alcohol beverages is as old as recorded 
history, and is of immense socio-cultural and religious significance. Ethanol, 
which is associated with a good feeling, is one of the most widely used, and 
abused, recreational drugs. Ethanol abuse in susceptible individuals leads to 
alcohol dependence, also known as alcoholism.
Ethanol Dependence
Ethanol dependence is an example of drug dependence. Drug dependence is a 
chronic neurological disorder characterized by behaviors including loss of control 
over drug use, compulsive use of a drug, and intense drug seeking. Drug 
dependence is associated with drugs that are able to affect the structure and 
function of the brain. These drugs target certain neuroanatomical structures and 
neurochemical systems that are also associated with natural reward, mood or 
pleasure. The target neuronal systems, which are thought to be involved in 
natural rewards, are hijacked by these addictive drugs and modified to
perpetuate compulsive drug use. 
Ethanol dependence (alcoholism) is one of the most widespread addictions. 
Alcoholism is medically classified as a disease. The Journal of the American 
Medical Association (JAMA) defines alcoholism as a primary chronic disease 
characterized by impaired control over drinking, preoccupation with the drug 
alcohol, use of alcohol despite adverse consequences, and distortions in thinking 
(Morse and Flavin, 1992). Indeed, alcoholism is a serious health concern, and in 
2001, the World Health Organization (WHO), through the Office of the Director 
General, estimated that 140 million people worldwide suffer from some form of 
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alcoholism (Mayor, 2001). Alcohol abuse and dependence have a huge impact 
on society, and therefore it is very important to understand the way ethanol 
interacts with the brain to generate addictive behavior, so that therapeutic 
interventions can be developed to manage the disease. What is it about ethanol 
that makes it an addictive drug? It is thought that the addictive effects may be 
due partly to the reinforcing effects of ethanol.
Assessment of drug reinforcement
We mentioned in the previous paragraph that ethanol abuse can lead to ethanol 
dependence. We concluded with the idea that ethanol is able to do this, in part, 
because it is a reinforcing drug. It is, therefore, important to briefly talk about drug 
reinforcement in order to enable us to understand why ethanol should be 
classified as a reinforcing drug. What is drug reinforcement? In very simple 
words, drug reinforcement can be defined as an increase in the importance of a 
drug to an organism such that there is an enhancement of a behavioral response 
aimed at obtaining the effect of the drug. The reinforcing properties of a drug can 
be measured using the following operant procedures.
Intracerebral self-stimulation (ICSS)
This is an operant technique that allows self-administration, through performance 
of a specific task, of a weak electrical current to discrete brain areas via an 
electrode (Olds and Milner, 1954). The electrical current causes an increase in 
the activity of target neurons, which in turn may lead to reinforcement. If a 
particular drug reduces the frequency of self-stimulation (ICSS), the drug may be 
reinforcing, in which case the subject need not administer more electrical current 
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(Bozarth et al., 1980). However, a reduction in self-stimulation may be due to 
locomotor- or motivation-impairing effects of a drug. If a particular drug increases 
responding for ICSS, it may also imply that the drug stimulates motivation, and 
may be rewarding. Generally, reinforcing drugs decrease ICSS threshold 
whereas non-reinforcing drugs either decrease or have no effect on ICSS 
threshold (Kornetsky et al., 1979).
Drug Self-administration
This is a very powerful tool for determining the reinforcing effect of a drug. In 
drug self-administration, the animal controls the delivery of a drug via different 
routes (oral, intravenous, intragastric, subcutaneous, and intracerebral) by 
pressing a lever in an operant chamber. If a particular drug is readily self-
administered, that drug satisfies the criteria for a reinforcing substance. 
Ethanol is a reinforcing drug
Ethanol affects ICSS. For instance, oral self-administration of low to moderate 
doses of ethanol increases responding for rewarding brain stimulation (Bain and 
Kornetsky, 1989). Self-administration of ethanol facilitated ICSS, whereas 
experimenter-delivered ethanol administration did not (Schaefer and Michael, 
1987; Kornetsky et al., 1988; Moolten and Kornetsky, 1990). The effects of 
ethanol on lateral hypothalamic ICSS are dependent on the duration of time after 
ethanol administration, with a decrease in reward threshold at < 20 min (Lewis 
and June, 1990) 
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Ethanol is self-administered through a variety of routes. For example, animal 
subjects self-administer ethanol intragastrically (Sinden et al., 1983; Waller et al., 
1984), intravenously (Smith and Davis, 1974; Sinden and Le Magnen, 1982; 
Lyness and Smith, 1992; Hyytia et al., 1996; Kuzmin et al., 1999; Grahame and 
Cunningham, 2002), orally (Grant and Samson, 1985; Samson et al., 1988, 
2003; Suzuki et al., 1988; Williams and Woods, 1998; Williams et al., 1998, 2001; 
Doyon et al., 2004, 2005, 2006) and directly into the ventral tegmental area 
(VTA) (Gatto et al., 1994; Rodd et al., 2004a, b, 2005). The summary of the 
above cited literature is that ethanol decreases ICSS threshold, and is self-
administered, and therefore fulfils the requirements of a reinforcing drug.
Ethanol reinforcement is thought to be involved in the mechanism of ethanol 
dependence. Ethanol 
dependence is thought to 
progress from an early 
impulsive stage to a late 
compulsive stage (Figure 
1.1) (Koob and Le Moal, 
2005). In the impulsive 
stage, the drive for 
ethanol-taking behavior is 
positive reinforcement. As 
individuals move to the 
compulsive stage, the 
drive transitions to 
Figure 1.1. Proposed stages of alcohol dependence. In 
the impulsive and compulsive stages, ethanol is taken 
for its rewarding and negative effect-relieving effects, 
respectively. Image is adapted from Heilig and Koob, 
2007.
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negative reinforcement, in which ethanol is taken to achieve the removal of the 
aversive state (Koob and Le Moal, 2005). In other words, in the early stages of 
ethanol dependence, ethanol is taken for its rewarding effects, but this soon 
progresses to a stage in which ethanol is taken to relieve negative effects that 
occur when ethanol is not used (Heilig and Koob, 2007) (Figure 1.1). Therapeutic 
interventions targeting ethanol reinforcement may provide benefit in the clinical 
management of alcoholism.
Clinical management of ethanol dependence
We have shown evidence to support the idea of ethanol as a reinforcing drug and 
described ethanol dependence as a disease. We have talked about how ethanol 
abuse affects the individual and the society as a whole, and we deem it important 
to talk about how society is trying to cope with alcoholism. There are many 
neurochemical mechanisms involved in ethanol dependence, and therefore, 
there are many possible pharmacological treatments in the clinical management 
of alcohol dependence (for review, see Heilig and Egli, 2006). The U.S. Food and 
Drug Administration (FDA) has so far approved only three medications –
disulfiram (Antabuse), naltrexone (Revia), and acamprosate (Campral)
(Buonopane and Petrakis, 2005). For this dissertation, we will focus on 
naltrexone. Naltrexone, a non-selective opioid antagonist, when combined with 
psychosocial treatments, decreases relapse and craving in alcohol dependent 
patients (O’Malley et al., 1992; Volpicelli et al., 1992; Anton et al., 1999; Chick et 
al., 2000; Heinala et al., 2001; Kiefer & Mann, 2005; Williams, 2005). In many 
pre-clinical studies, naltrexone suppressed ethanol reinforcement (Altshuler et 
al., 1980; Phillips et al., 1997; Bienkowski et al., 1999; Middaugh et al., 1999). 
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However, some human studies did not find an efficacy for naltrexone (Kranzler et 
al., 2000; Krystal et al., 2001), probably partly due to poor compliance. Overall, it 
seems that naltrexone offers marginal benefits. The clinical application of 
naltrexone in the management of alcohol dependence necessitates a discussion 
of the endogenous opioid system.
THE ENDOGENOUS OPIOID SYSTEM
Discovery of the endogenous opioid peptides and receptors
The discovery of the endogenous opioid system started with the observation that 
morphine exerts very profound 
biological effects. Morphine is an opioid 
alkaloid or opiate (Figure 1.2). The 
biological effects of opiates, such as 
morphine, have been known since 
antiquity, but the knowledge of opiate 
pharmacology was not established 
before the 20th century. Opioid comes 
from the word ‘opium’ which is the dried 
milky juice or latex of the unripe seed 
capsule of the poppy plant (Papaver somniferum). Use of opium poppies for 
food, analgesia, anesthesia, and ritual purposes dates back to at least the 
Neolithic Age (9500 BCE). The first known cultivation of opium poppies was by 
Sumerians in Mesopotamia ~3400 B.C. (Brownstein, 1993). With the widespread 
use of opium, its addictive effects became apparent. During the Renaissance 
period, opium was introduced as a tincture (laudanum) in 1527 by the physician 
Figure 1.2. The chemical structure of 
morphine ((5α, 6α)-7, 8-didehydro-4, 5-
epoxy-17-methylmorphinan-3, 6-diol).
Structure reproduced with permission 
from Sigma-Aldrich.
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Paracelsus (1493-1541) for use as a medicinal remedy for a number of 
indications. Opium is still being used today. Now, opium is known to contain 
narcotic opiate alkaloids such as morphine, codeine and non-narcotic alkaloids, 
such as papaverine and noscapine. Morphine was first isolated in 1804 by the 
German pharmacist Friedrich Wilhelm Adam Sertürner, who named it ‘morphium’ 
(after Morpheus - the Greek god of dreams). Morphine is a very effective 
analgesic and its use as a pain reliever continues to this day. However, morphine 
is also a very addictive substance. The discovery of morphine and other opiates 
and the search for non-addictive opiates has led to extensive characterization of 
opioid pharmacology.
Based on the unique structural requirements of opiates, the existence of a 
specific opiate receptor was proposed (Beckett and Casy, 1954a, b). Opiate 
biological function was observed in guinea pig ileum (Cowie et al., 1970), and 
subsequently, opiate-binding sites were discovered in the central nervous system 
(CNS) (Goldstein et al., 1971; Pert and Snyder, 1973a, b; Simon, 1973; Terenius, 
1973). In the early 1970s, it was suggested that morphine mimicked certain 
substances present naturally in the body. The existence of morphine-like 
endogenous ligands became a subject of interest when it was observed that 
naloxone, an opiate antagonist, caused aversion in opiate-naïve subjects, and 
reversed stimulation-induced analgesia. It was hypothesized that the stimulation-
induced analgesia occurred as a result of the activation of an endogenous opiate 
pain modulating system. This idea was supported by the observation that an 
opiate antagonist (by blocking this endogenous system) reversed this 
stimulation-induced analgesic effect. In summary, the discovery of the 
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endogenous opiate binding sites, the intrinsic activity of opiate antagonists in 
opiate naïve subjects, and the attenuation of non-drug induced analgesia by 
opiate antagonists, all inspired the idea of the existence of an endogenous 
system (including endogenous opioid ligands and receptors) (Akil et al., 1976; 
Buchsbaum et al., 1977).
The existence of endogenous opioids was confirmed by research studies that led 
to the characterization of enkephalins, the first discovered endogenous opioids 
(Hughes et al., 1975). Further research led to the discovery of other opioid 
peptides including β-endorphin and dynorphin (Goldstein, 1976; Goldstein et al., 
1979). The endogenous opioids: β-endorphin, enkephalins and dynorphins are
formed by enzymatic processing of three precursor molecules, pro-
opiomelanocortin (POMC), proenkephalin, and prodynorphin, respectively 
(Nakanishi et al., 1979; Comb et al., 1982; Kakidani et al., 1982; Noda et al., 
1982). The search for other endogenous opioid peptides has led to the discovery 
of the endomorphins (endomorphin-1 and endomorphin-2) (Hackler et al., 1997; 
Zadina et al., 1997, 1999). Also, [D-Ala2] deltorphin I has been detected in the 
brain (Tooyama et al., 1993; Casini et al., 2004).
The concept of opioid receptors arose after the demonstration of opioid-binding 
sites (see discussion above). Behavioral and neurophysiological findings in the 
chronic spinal dog distinguished mu (µ), kappa (κ), and sigma (σ) opioid 
receptors. The mouse vas deferens exhibited higher affinity for the enkephalins 
than for morphine, leading to the proposal for the existence of a distinct 
enkephalin vs morphine preferring site termed delta (δ) - a receptor that is also 
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widely distributed in the CNS (Lord et al., 1977; Chang and Cuatrecasas, 1979). 
The σ receptor does not mediate naloxone-reversible effects and is no longer 
classified as an opioid receptor. The opioid receptors (µ, δ, and κ) have been 
isolated, purified and characterized (Simon, 1987a, b; Reisine, 1995). In addition, 
the human genomic coding regions for these opioid receptors have been 
identified (Befort et al., 1994; Simonin et al., 1994; Wang et al., 1994; Yasuda et 
al., 1994).
The differentiation in the binding properties and biological effects of similar opioid 
ligands has led to the idea of the existence of subtypes of the opioid receptors 
(Wolozin and Pasternak, 1981; Lutz et al., 1984; Pasternak, 1986; De Costa et 
al., 1989; Rothman et al., 1989; Jiang et al., 1991; Negri et al., 1991; Wollemann
et al., 1993; Hiller et al., 1996). These opioid receptor subtypes include µ1, µ2, 
δ1, δ2, κ1, κ2, κ3 (Dhawan et al., 1996). Recently, there has even been 
suggestion of an opioid-peptide insensitive, opioid alkaloid-sensitive µ3-opioid 
receptor (Stefano et al., 2008). However, the existence of opioid receptor 
subtypes is controversial because there is no genetic evidence to back up their 
existence. Subtypes of the opioid receptors may arise from post-translational 
modification of the receptor (for review, see Wei et al., 2004).
Opioid receptor pharmacology
Opioid receptor signaling mechanisms
The three major opioid receptors (µ, δ, and κ) have similar molecular structures 
and belong to the family of seven transmembrane G-protein coupled receptors. 
They have been cloned using molecular biological techniques (Evans et al., 
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1992; Kieffer et al., 1992; Chen et al., 1993a, b; Meng et al., 1993; Minami et al., 
1993; Thompson et al., 1993; Wang et al., 1993; Yasuda et al., 1993; Uhl et al., 
1994; Knapp et al., 1995). Activation of the opioid receptors leads to the 
activation of Gi/o protein causing the inhibition of adenylate cyclase and a 
reduction in cAMP, decreases in calcium channel conductance, and increases in 
potassium channel conductance (Grudt and Williams, 1995; Law et al., 2000). 
Opioid receptor interactions
In addition to the structural and functional characterization of µ-, δ-, and κ-opioid 
receptors (Simon, 1987a, b; Goldstein and Naidu, 1989), µ- and δ-opioid 
receptors may dimerize to form 
physically coupled opioid receptors 
(Schoffelmeer et al., 1988, 1989, 
1990a, b; Heyman et al., 1989a, b; 
Jiang et al., 1990; Traynor and 
Elliot, 1993; Jordan and Devi, 1999; 
George et al., 2000; Gomes et al., 
2000; Levac et al., 2002; Wang et 
al., 2005; Snook et al., 2006; 
Rutherford et al., 2008) or may 
interact through non-coupled receptor cross-talk (Sheldon et al., 1989; Malmberg 
and Yaksh, 1992; Palazzi et al., 1996). The µ- and δ-opioid receptor interactions 
are illustrated in Figure 1.3. Alt et al. (2002) published findings supporting the 
hypothesis that µ- and δ-opioid receptors share a common G protein pool, 
possibly through a close organization of the two receptors and G protein at the 
Figure 1.3. Opioid receptor interactions. δ-
and µ-opioid receptors can interact through 
non-coupled receptor interaction or through 
physically coupled δ-µ-opioid receptor 
heterodimerization.
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plasma membrane. Furthermore, Charles et al. (2003) showed that under certain 
conditions, an interaction occurs between µ- and δ-opioid receptors leading to a 
change in the functional response to µ-opioid activation.
Some of the evidence regarding the existence of this µ-δ-opioid receptor 
interaction comes from research looking at the biological activity of [D-Pen2-D-
Pen5] enkephalin (DPDPE). DPDPE is a very selective δ-opioid agonist with 
1000 fold affinity for δ-opioid compared to µ- and κ-opioid receptors (Raynor et 
al., 1994; George et al., 2000). However, selective genetic knockout (Sora et al., 
1997; Fuchs et al., 1999; Matthes et al., 1998; Hosohata et al., 2000; Scherrer et 
al., 2004), and selective pharmacological blockade (Fraser et al., 2000), of the µ-
opioid receptor resulted in an attenuation of DPDPE-mediated antinociception. It 
is important to understand that in these µ-opioid receptor knockout mice, δ-opioid 
receptor density is intact (Kitchen et al., 1997). The evidence suggests that 
DPDPE is binding at the δ-opioid receptor but also recruiting the µ-opioid 
receptor.
Selectivity of the endogenous opioid peptides for opioid receptors
The endogenous opioid peptides, as expected, interact with the opioid receptors 
(Reisine, 1995). However, the endogenous opioid peptides are not very 
selective, and bind to the various opioid receptors with differing affinities (Hughes 
et al., 1980; Goldstein and Naidu, 1989). For instance, β-endorphin has affinity 
and efficacy at the µ- and δ-opioid receptor (Spanagel et al., 1990a; Reisine, 
1995), including activity at the µ1-opioid receptor (Houghten et al., 1984). 
However, β-endorphin also binds to a single protein in the rat striatum that has 
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affinity for µ- and δ-opioid receptor ligands, but in addition has a higher molecular 
weight than individual µ- and δ-opioid receptors (Schoffelmeer et al., 1989, 
1990a, b). This is proposed to be the physically coupled µ-δ opioid receptor 
complex (Schoffelmeer et al., 1989, 1990a, b; Bals-Kubik et al., 1990). With 
regards to µ- and δ-opioid properties, β-endorphin displays affinity in the order µ-
δ > δ > µ (George et al., 2000). Other endogenous opioid peptides also bind to 
various opioid receptors. For instance, the opioid peptides- met- and leu-
enkephalins- have high affinity at µ-, δ-, and the µ-δ-opioid receptor complex 
(George et al., 2000). Enkephalins act at both the µ- and δ-opioid receptor with 
affinity for δ > µ (Hughes et al., 1980; Raynor et al., 1994; Reisine, 1995). 
Endomorphin-1 and -2 have a high affinity for the µ-opioid receptor (Monory et 
al., 2000). Dynorphins have some activity at all opioid receptors (Quirion and 
Pert, 1981; Zhang et al., 1998), but display a higher selectivity for the κ-opioid 
receptor (Chavkin et al., 1982; James et al., 1982). The endogenous opioid 
peptides and their target opioid receptors are summarized in Table 1.2.
Table 1.2. The endogenous opioid peptides and their target opioid receptors.
Opioid peptide Target receptor(s)
β-endorphin µ, δ, µ-δ





Pharmacology of the µ-opioid antagonists
After the discovery of the endogenous opioid peptides and opioid receptors, and 
further advances in opioid chemistry, opioid receptor antagonists were 
developed. Receptor binding of opioid agonists and antagonists can be 
differentiated in vivo and in vitro, with opioid antagonists having 10-1000 fold 
more potency than agonists (Pert et al., 1973). Like the endogenous opioid 
peptides, opioid antagonists have differing affinities for µ-, δ-, κ-opioid, and the µ-
δ-opioid receptor complex (Raynor et al., 1994; George et al., 2000). In this 
section, we will focus on µ-opioid antagonists and discuss a few of them that are 
relevant to this dissertation.
Naltrexone
Naltrexone (Figure 1.4) reversibly 
blocks all opioid receptors, though it 
has a 150-fold higher affinity for µ-
compared to δ-, and a 4-10-fold higher 
affinity for µ- compared to κ-opioid 
receptors (Goldstein and Naidu, 1989; 
Emmerson et al., 1994; Raynor et al., 
1994; Reisine, 1995). The naltrexone 
opioid-inhibition order is µ > κ >> δ 
(Takemori and Portoghese, 1984; 
Goldstein and Naidu, 1989; Emmerson et al., 1994; Peng et al., 2007). Another 
non-selective opioid antagonist that is well known is naloxone. Naltrexone has 
Figure 1.4. The chemical structure of the 
non-selective reversible opioid antagonist: 
Naltrexone ((5α)-17-(Cyclopropylmethyl)-
4, 5-epoxy-3, 14-dihydromorphinan-6-one 
hydrochloride). Structure reproduced with 
permission from Sigma-Aldrich.
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greater affinity and selectivity than naloxone for the µ-opioid receptor. For 
instance, compared to naloxone, naltrexone has 2-fold greater selectivity for µ-
over the κ-, and a 9-fold greater selectivity for µ- over the δ-opioid receptors 
(Goldstein and Naidu, 1989; Raynor et al., 1994). Naltrexone is also more potent 
than naloxone in antagonizing the effects of morphine (Shannon and Holtzman, 
1976; Takemori and Portoghese, 1984). Furthermore, naltrexone has a longer 
duration of action than naloxone (Shannon and Holtzman, 1976).
β-funaltrexamine
β-funaltrexamine (Figure 1.5) is a long-lasting, selective, irreversible µ-opioid 
antagonist (Ward et al., 1982, 1985). It acts by irreversible alkylation of the µ-
opioid receptors (Elliott et al., 1994; Liu-Chen and Phillips, 1987).
Figure 1.5. The chemical structure of the selective irreversible µ-opioid antagonist: β-
funaltrexamine ((E)-4-[[5α, 6β)-17-Cyclopropylmethyl)-4, 5-epoxy-3, 14-dih 
ydroxymorphinan-6-yl] amino]-4-oxo-2-butenoicacid methyl ester hydrochloride). 
Structure reproduced with permission from Sigma-Aldrich.
16
β-funaltrexamine is selective for the µ-opioid receptor (Liu-Chen and Phillips, 
1987; Liu-Chen et al., 1990, 1991). β-funaltrexamine has a 36-fold selectivity for 
µ- compared to δ- and a 7-fold selectivity for µ- compared to κ-opioid receptors 
(Tam and Liu-Chen, 1986). 
β-funaltrexamine blocks the effects of the highly selective µ-opioid receptor 
agonist: [D-Ala2,NMe-Phe4,Gly5-ol]-enkephalin (DAMGO) (Hayes et al., 1985). 
However, some studies conclude that β-funaltrexamine inhibits the effects of δ-
agonists (Dray et al., 1985; Hayes et al., 1985). Further analysis shows that 
Hayes et al. (1985) used the δ-opioid agonists- [D-Ala2, D-Leu5] enkephalin 
(DADLE) and [D-Ser2, Leu5] enkephalinyl-Thr6 (DSLET). Goldstein and Naidu 
(1989) determined that DADLE and DSLET barely distinguish δ- from µ-opioid 
receptors, and therefore, the conclusion that β-funaltrexamine inhibits the effects 
of δ-agonist (in this case DADLE and DSLET) needs to be taken with caution. In 
addition, Dray and colleagues (1985) reported that β-funaltrexamine inhibits the 
effects of the δ-agonist: DPDPE. However, DPDPE has a very complex 
pharmacology (as described above in section on opioid receptor interactions),
including the possibility of DPDPE acting through δ-opioid and µ-opioid receptor 
interaction (Figure 1.3). Therefore, it is likely that β-funaltrexamine is inhibiting 
the actions of DPDPE, by blocking the µ-opioid component of the µ-δ-opioid 
receptor interaction (see Figure 1.3), and not the δ-opioid receptor. This idea has 
been confirmed by studies showing that β-funaltrexamine also binds to the µ-δ 
opioid receptor complex (Rothman et al., 1988, 1991). All the evidence suggests 
that β-funaltrexamine is selective for the µ-opioid receptor and the µ-opioid 
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component of a µ-δ-opioid receptor complex. The idea that β-funaltrexamine is 
active at the δ-opioid receptor needs to be reassessed. 
Naloxonazine
Naloxonazine, postulated to be a selective, irreversible µ1-opioid antagonist (Ling 
et al., 1986), blocked both DAMGO and DPDPE effects (Dray and Nunan, 1984; 
Dray et al., 1985, 1987). The assumption that naloxonazine may be significantly 
blocking the δ-opioid receptor (Dray and Nunan, 1984; Dray et al., 1985, 1987), 
has been predicated on another flawed assumption that DPDPE effects the 
action in question exclusively via a δ-opioid receptor (see discussion on opioid 
receptor interactions above). This assumption needs to be carefully considered 
because naloxonazine does not have any significant affinity for the δ-opioid 
receptor, and DPDPE has no significant affinity for the µ-opioid receptor (Raynor 
et al., 1994; George et al., 2000). Naloxonazine has ~200-fold more affinity for µ-
compared to δ-opioid receptors (Raynor et al., 1994). It is possible that 
naloxonazine (similar to β-funaltrexamine) is blocking µ1-opioid receptors 
involved in an interaction with δ-opioid receptors (see Figure 1.3, sections on 
opioid receptor interactions and β-funaltrexamine). However, the µ-δ-opioid 
receptor complex is not sensitive to blockade by naloxonazine (Heyman et al., 
1989a), and therefore blockade at µ1-opioid receptors functionally (but not 
physically) coupled to a δ-opioid receptor, may explain why naloxonazine 
blocked DPDPE effects (Dray and Nunan, 1984). Additionally, DPDPE may bind 
with low affinity to the µ1-opioid receptor (Clark et al., 1986). The evidence 
suggests that naloxonazine may be blocking the µ1-opioid component of the 
effects of DPDPE (Clark et al., 1986), and not the δ-opioid receptor. 
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THE ENDOGENOUS OPIOID SYSTEM PLAYS AN IMPORTANT ROLE IN 
ETHANOL REINFORCEMENT
We have introduced the endogenous opioid system by discussing the component 
parts including endogenous opioid peptides and receptors. We mentioned a few 
important opioid antagonists. Here, we will discuss evidence from 
pharmacological, genetic, and selective breeding studies, showing that the 
endogenous opioid system plays a role in ethanol reinforcement. 
The endogenous opioid peptides are reinforcing
Endogenous opioid peptides are reinforcing (for reviews, see Van Ree et al., 
1999, 2000; Vaccarino and Kastin, 2001). For example, β-endorphin causes 
conditioned place preference (Amalric et al., 1987; Bals-Kubik et al., 1990). 
Enkephalins are self-administered by laboratory animals (Belluzzi and Stein, 
1977; Goeders et al., 1984a, b). D-Ala2-Met5-enkephalinamide (a synthetic 
analog of met-enkephalin) produces facilitation of ICSS (Broekkamp and Phillips, 
1979), and conditioned place preference when microinjected into the VTA 
(Phillips and LePiane, 1982). Endomorphin-1 and -2 produce conditioned place 
preference when administered into the VTA (Terashvili et al., 2004). In general, 
β-endorphin, enkephalins, and endomorphins are rewarding, as they are self-
administered by laboratory animals whilst the pharmacological profile of 
dynorphin seems to be different from that of β-endorphin and enkephalins (for 
reviews, see Van Ree et al., 1999).
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Even though dynorphin is generally thought to cause aversive effects, there is 
some evidence to the contrary. For instance, dynorphin A (1-17) caused 
conditioned place preference (Iwamoto, 1988, 1989) and dynorphin B, when 
injected into the VTA, facilitated the self-stimulation rates of the VTA (Singh et 
al., 1994). There is some evidence that dynorphin binds to all the opioid 
receptors (µ, δ and κ) with high affinity (Zhang et al., 1998). Dynorphin A is self-
administered into the CA3 region of the hippocampus, but this rewarding effect of 
dynorphin may be due to actions at the µ-opioid receptor (Stevens et al., 1991). 
Also, endomorphin-2 is reinforcing, but it increases dynorphin levels in the brain 
(Narita et al., 2001, 2002; Tseng et al., 2002; Wu et al., 2003; Terashvili et al., 
2005; Mizoguchi et al., 2006), suggesting that some of the reinforcing effects of 
endomorphin-2 may even be mediated via dynorphin. Dynorphin may have some 
reinforcing effects under certain conditions.
In the assessment of drug reinforcement (as discussed in a previous section), µ-
and δ-opioid-activating ligands are reinforcing, whereas κ-opioid ligands are not
(Van Ree et al., 1999). For instance, intra-VTA administration of DAMGO 
(selective µ-opioid agonist) and U50488H (selective κ-opioid agonist) produce 
conditioned place preference and place aversion, respectively (Bals-Kubik et al., 
1993). In other studies, the selective µ- and δ-opioid agonists, DAMGO and 
DPDPE, respectively, were self administered into the VTA (Devine and Wise, 
1994). In summary, the endogenous opioid peptides, when acting through µ- and 
δ-opioid receptors, produce reinforcing effects.
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The endogenous opioid peptides are involved in ethanol intake and 
reinforcement
In the previous paragraph, we mentioned that the endogenous opioid peptides
may activate µ- and δ-opioid receptors to produce reinforcement. It is thought 
that ethanol may derive some of its reinforcement through the endogenous opioid 
peptides (Herz, 1997). It has been suggested that a genetic susceptibility to high 
alcohol drinking is correlated with plasma β-endorphin activity (Gianoulakis and 
de Waele, 1994; Gianoulakis, 1996, 2001). Plasma β-endorphin levels were 
found to be lower in alcoholics compared to normal subjects (Aguirre et al., 1990; 
Vescovi et al., 1992). In human studies, plasma levels of subjects genetically at 
high risk for excessive alcohol consumption showed lower basal activity of β-
endorphin, and more pronounced release of β-endorphin in response to ethanol 
(Gianoulakis et al., 1989; Gianoulakis et al., 1996). In rats, β-endorphin interferes 
with the acquisition and initial maintenance of ethanol preference (Sandi et al., 
1989). When administered into the nucleus accumbens (NAc) shell, β-endorphin 
(1-27), an inhibitor of β-endorphin activity (Spanagel et al., 1991b), inhibits
ethanol intake in rats (Resch et al., 2005). The evidence suggests that β-
endorphin is important in ethanol intake and in a predisposition to excessive 
alcohol consumption.
The evidence suggests that enkephalin activity in the brain may affect ethanol 
intake. Inhibition of aminopeptidase (which leads to an increase in enkephalins)
attenuates ethanol intake in rats (Szczepanska et al., 1996b, c). Sandi et al. 
(1990b) determined that in rats, D-Ala2-Met5-enkephalinamide (a synthetic 
analog of met-enkephalin) markedly impaired the acquisition of ethanol 
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preference. Furthermore, in addition to the impairment of the acquisition of 
ethanol preference, enkephalins also suppress voluntary ethanol intake (Sandi et 
al., 1990a, c). Enkephalin concentrations in the brain correlate inversely with 
ethanol intake and the predisposition of different strains of mice to drink ethanol
(Blum et al., 1983; Banks and Kastin, 1989). This is buttressed by studies in mice 
predisposed to high ethanol intake, which show that the administration of 
enkephalinase inhibitors (which raise brain enkephalin levels) decrease voluntary 
ethanol intake (Blum et al., 1987). There is data showing that preproenkephalin 
in the brain is involved in the modulation of neuroadaptative mechanisms 
associated with the decrease of ethanol intake induced by naltrexone (Oliva and 
Manzanares, 2007). While the brain enkephalin levels play a role in ethanol 
intake, there is evidence suggesting that plasma enkephalin levels may not be as 
important. For example, Vescovi et al. (1992) did not find a difference in plasma 
met-enkephalin levels between alcoholics and normal subjects. 
It is worth mentioning, that apart from endogenous opioid peptides, endogenous 
opioid alkaloids called tetrahydroisoquinolines (TIQ) can increase ethanol place 
preference and voluntary ethanol intake (Duncan and Deitrich, 1980). High and 
low concentrations of tetrahydropapaveroline (THP, a TIQ) suppress and 
enhance alcohol preference, respectively (Myers and Oblinger, 1977; Blum et al., 
1978). However, not all studies have observed ethanol intake following 
administration of THP (Smith et al., 1980), and others question the relevance of 
the supporting data (Smith and Amit, 1987; McCoy et al., 2003). The alcohol 
reinforcing effects of TIQs can be suppressed by naloxone and naltrexone, 
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suggesting that TIQs activate opioid receptors (Myers and Critcher, 1982; 
Critcher et al., 1983; Myers, 1989, 1990).
The results obtained from studies looking at the effects of the deletion of opioid 
peptides on ethanol reinforcement are mixed. For example, β-endorphin 
wildtypes have a higher preference for ethanol than their knockout littermates 
(Racz et al., 2008). However, there is conflicting data that indicates that β-
endorphin knockouts do not have a lower consumption for ethanol compared to 
their wildtype littermates (Grisel et al., 1999; Grahame et al., 2000; Hayward et 
al., 2004). Also, enkephalin wildtype and knockout mice do not show any 
differences in ethanol consumption and preference (Koenig and Olive, 2002; 
Hayward et al., 2004). Blednov et al. (2006) showed that prodynorphin knockout 
mice had reduced ethanol consumption. It is important to take into consideration 
the compensatory changes due to the deletion of the opioid peptide gene. For 
instance, both enkephalin and dynorphin knockout mice have significant 
upregulation of µ- and δ-opioid receptor expression (Brady et al., 1999; Clarke et 
al., 2003), together with alterations of other endogenous opioid peptide systems.
The opioid receptors are involved in ethanol intake and reinforcement
Pharmacological studies
Opioid agonists regulate ethanol intake. Low doses of morphine (1-2.5 mg/kg) 
increase ethanol intake (Hubbell et al., 1986, 1987, 1988a, b, 1993; Reid and 
Hunter, 1984; Reid et al., 1986, 1987, 1991; Reid, 1996; Wild and Reid, 1990; 
Sromberg et al., 1997), whereas high doses of morphine (10-60 mg/kg) decrease 
ethanol intake (Sinclair et al., 1973; Volpicelli et al., 1991). Also, morphine 
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suppressed the rebound consumption of ethanol displayed after a period of 
abstinence to free-choice ethanol in Wistar rats (Sinclair et al., 1973; Sinclair, 
1974). Microinfusion of DAMGO into the NAc increased the intake of ethanol 
(Zhang and Kelley, 2002). 
Opioid antagonists suppress ethanol intake and reinforcement. There are 
numerous data to show that non-selective and selective opioid antagonists 
suppress ethanol reinforcement (see Tables 1.3, 1.4 and 1.5).




Nalmefene Hubbell et al., 1991; Mason et al., 1994, 1999; Karhuvaara et 
al., 2007; Walker and Koob, 2008
Naloxone Lorens and Sainati, 1978; Marfaing-Jallat et al., 1983; Sinden 
et al., 1983; Pulvirenti and Kastin, 1988; Sandi et al., 1988; 
Froehlich et al., 1990; Hyytia and Sinclair, 1993; Hyytia et al., 
1999; Overstreet et al., 1999
Naltrexone Gonzales and Weiss, 1998; Stromberg et al., 1998a, b; 
Coonfield et al., 2002, 2004; Kiefer et al., 2005; Resch et al., 
2005; Higley and Kiefer, 2006; Kuzmin et al., 2008; Gilpin et 
al., 2008
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Table 1.4. Naltrexone, a non-selective opioid antagonist, inhibits ethanol intake and 
reinforcement in different mammalian species.
Species Selected references
Mice Phillips et al., 1997; Middaugh et al., 1999; Middaugh and 
Bandy, 2000; Middaugh et al., 2000; Fachin-Sheit et al., 2006; 
Kamdar et al., 2007
Rats Franck et al., 1998; Gonzales and Weiss, 1998; Stromberg et al., 
1998a, b; Ciccocioppo et al., 2002; Coonfield et al., 2002, 2004; 
Parkes and Sinclair, 2002; Heyser et al., 2003; Pickering and 
Liljequist, 2003; Stromberg, 2004; Kiefer et al., 2005; Resch et 
al., 2005; Burattini et al., 2006; Higley and Kiefer, 2006; Sabino 
et al., 2006; Jimenez-Gomez and Shahan, 2007; Kuzmin et al., 
2008; Gilpin et al., 2008
Non-human 
primates
Altshuler et al., 1980; Myers et al., 1986; Kornet et al., 1991; 
Boyle et al., 1998; Williams and Woods, 1998; Williams et al., 
1998, 1999
Humans O’Malley et al., 1992, 2002; Volpicelli et al., 1992; Swift, 1995
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Table 1.5. Effects of selective opioid antagonists on ethanol intake in rats.
Antagonists Target Ethanol intake Selected references
β-funaltrexamine µ decrease Krishnan-Sarin et al., 1998; 
Stromberg et al., 1998a
CTOP µ decrease HyytЇa , 1993 (i.c.v.); HyytЇa 
and Kiianmaa, 2001 (i.c.v.)
Naloxonazine µ1 decrease, no 
effect
Honkanen et al., 1996; 
Franck et al., 1998; Mhatre 
and Holloway, 2003
Naltrindole δ decrease Krishnan-Sarin et al., 1995a; 
HyytЇa and Kiianmaa, 2001 
(i.c.v.)
SoRI-9409 δ decrease Nielsen et al., 2008
ICI-174,864 δ decrease, no 
effect
HyytЇa, 1993 (i.c.v.); 
Krishnan-Sarin et al., 1995a; 
Franck et al., 1998;
Natriben δ2 decrease Krishnan-Sarin et al., 1995b; 
June et al., 1999
N,N(CH3)2-Dmt-
Tic-OH
δ no effect Ingman et al., 2003
Nor-BNI κ increase Mitchell et al., 2005
CTOP = D-Pen-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2, i.c.v = intracerebroventricular. 
SoRI-9409 = 5'-(4-chlorophenyl)-17-(cyclopropylmethyl)-6,7-didehydro-3,14-dihydroxy-
4,5α-epoxypyrido-[2',3':6,7]morphinan, ICI 174,864 = allyl2-Tyr-Aib-Aib-Phe-Leu-OH , 
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As we mentioned previously, naltrexone, a non-selective opioid antagonist, is 
FDA approved for the management of ethanol dependence. Pre-clinical and 
clinical data show that naltrexone can attenuate ethanol drinking behavior, 
(Tables 1.3 and 1.4). By what mechanism does naltrexone attenuate ethanol 
intake? Because naltrexone is non-selective, it is important to find out which 
specific opioid receptor, if any, is involved in its effects. There is evidence that 
selective µ-opioid antagonists decrease ethanol reinforcement. For instance, β-
funaltrexamine attenuates ethanol intake in rats (Krishnan-Sarin et al., 1998; 
Stromberg et al., 1998a). Also, in rats, naloxonazine, a selective µ1-opioid 
antagonist, antagonizes some reinforcing effects of ethanol and suppresses 
ethanol consumption (Honkanen et al., 1996; Mhatre and Holloway, 2003), 
though Franck et al. (1998) did not show a naloxonazine-mediated suppression 
of ethanol intake. Furthermore, Honkanen et al. (1996) showed that naloxonazine 
was insufficient to cause a sustained decrease in alcohol drinking. There is 
evidence that naloxonazine inhibits ethanol-seeking behavior due to associated 
drug-related environmental stimuli (Ciccocioppo et al., 2002). 
There are also data supporting a role for the δ-opioid receptor in ethanol 
reinforcement. For instance, naltrindole, a selective δ-opioid receptor antagonist, 
inhibits ethanol-seeking behavior due to associated drug-related environmental 
stimuli (Ciccocioppo et al., 2002). In addition, SoRI-9409, a novel δ-opioid 
receptor antagonist, causes selective and long-lasting reductions of ethanol 
consumption (Nielsen et al., 2008), though it is important to note that SoRI-9409 
also activates the µ-opioid receptor (Wells et al., 2001). Furthermore, there was 
also a significant reduction in ethanol intake following administration of the δ-
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opioid receptor antagonist- ICI-174,864 (Franck et al., 1998). Naltriben, a 
selective δ2-opioid receptor antagonist, suppressed ethanol self-administration 
(June et al., 1999). Intracerebroventricular naltrindole suppresses ethanol self-
administration in rats (Hyytia and Kiianmaa, 2001). However, Margolis et al. 
(2008) show that intra-VTA administration of a selective δ-opioid receptor agonist
(DPDPE) and antagonist (TIPP-ψ) decrease and increase ethanol intake in low 
ethanol drinking rats, respectively. Also, N, N (CH3)2-Dmt-Tic-OH, a selective δ-
opioid antagonist, does not reduce ethanol intake in alcohol-preferring AA rats 
(Ingman et al., 2003). The role of the δ-opioid receptors in ethanol intake and 
reinforcement is not clear. For instance, there is evidence that δ-opioid 
antagonists may enhance, suppress, or not affect ethanol intake under different 
conditions.
The effects of opioid antagonists on ethanol reinforcement are centrally 
mediated, since opioid antagonists that do not cross the blood brain barrier do 
not suppress ethanol intake (Linseman, 1989). This is supported by data showing 
that centrally located opioid receptors in the VTA, NAc, amygdala and 
hippocampus (Heyser et al., 1999; Myers and Robinson, 1999; Hyytia and 
Kiianmaa, 2001; Foster et al., 2004; June et al., 2004; Bechtholt and 
Cunningham, 2005; Lasek et al., 2007) have been implicated in ethanol intake 
and reinforcement.
It is important to mention that it has also been proposed that the effects of opioid 
antagonists may not be specific for the attenuation of ethanol reinforcement, but 
may be a general suppression of appetitive and consummatory behavior (Reid 
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and Hunter, 1984; Koob and Weiss, 1990; Weiss et al., 1990; Schwarz-Stevens 
et al., 1992; Biggs and Myers, 1998; Williams et al., 1998; Williams and Woods, 
1999). Others argue that the opioid antagonists, when administered at lower 
doses (Froehlich et al., 1990) are specific for ethanol reinforcing effects 
compared to natural reinforcers. This idea is still controversial.
Genetic studies
Unlike the results from the deletion of opioid peptides, studies looking at opioid 
receptor deletions are more consistent. Mice without the µ-opioid receptor have 
decreased ethanol intake (Hall et al., 2001; Becker et al., 2002) and self-
administration (Roberts et al., 2000). In addition, selective regional knockdown of 
the µ-opioid receptor gene through antisense and RNA interference in the NAc 
and VTA, respectively, led to suppression of ethanol intake (Myers and 
Robinson, 1999; Lasek et al., 2007). Unfortunately, µ-opioid receptor knockout 
mice have been shown to have increased proenkephalin gene expression and 
increased δ-opioid receptor binding (Tien et al., 2007), and the compensatory 
changes due to the gene deletion may contribute to the decrease in ethanol 
reinforcement observed. Fortunately, studies utilizing selective pharmacological 
antagonists also reached the same conclusions with regard to a role for the µ-
opioid receptor in ethanol intake and reinforcement. For instance, selective opioid 
antagonists: β-funaltrexamine (Krishnan-Sarin et al., 1998; Stromberg et al., 
1998a) and CTOP (Hyytia and Kiianmaa, 2001) are effective in suppressing 
ethanol intake in rats. The results from opioid receptor gene deletion studies for 
the other receptors are unexpected. For example, δ-opioid receptor knockout 
mice showed an increase in ethanol self-administration (Roberts et al., 2001) and 
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κ-opioid knockout mice showed decreased oral ethanol self-administration 
(Kovacs et al., 2005).
Selective breeding studies
One way to look at the impact of a receptor on ethanol reinforcement is to try and 
determine if the receptor is differentially expressed in high vs low alcohol 
preferring animal models. Table 1.6. shows some differences between strains 
bred for high and low ethanol drinking.
Table 1.6. Differences in opioid peptides and receptors in the brain between high and 
low ethanol-preferring rat and mice strains (adapted from Murphy et al., 2002).
Differences Selected references
β-endorphin ANA>AA Gianoulakis et al., 1992; De Waele and 
Gianoulakis, 1994
Enkephalin sP>sNP; P=NP; 
ANA>AA; FH<WKY; 
C57BL/6>DBA/2
Nylander et al., 1994; Cowen et al., 1998; Li et 
al., 1998; Fadda et al., 1999; Jamensky and 
Gianoulakis, 1999
µ AA>ANA; sNP>sP; 
LAD>HAD
De Waele et al., 1995; Gong et al., 1997; Soini et 
al., 1998; Fadda et al., 1999; Marinelli et al., 
2000 
δ AA>ANA; NP>P; 
DBA/2>C57BL/6
De Waele et al., 1995; De Waele and 
Gianoulakis, 1997; Soini et al., 1998; Strother et 
al., 2001
Alcohol-preferring/ alcohol non-preferring = P/NP; HAD/LAD; AA/ANA; sP/sNP; C57BL/6/ 
DBA/2; FH/WKY (Fuller, 1964; McBride and Li, 1998; Murphy et al., 2002)
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We have shown through a wide range of pharmacological, genetic, and selective 
breeding studies, evidence that the endogenous opioid system is involved in 
ethanol reinforcement. Of the opioid receptors, the µ-opioid receptor is thought to 
play a major role in ethanol reinforcement. Indeed, there is evidence implicating a 
role for the µ-opioid receptor genes in specific brain regions in the modulation of 
neuroadaptative mechanisms associated with the decrease of ethanol intake 
induced by naltrexone (Oliva and Manzanares, 2007). This is further reinforced 
by some pre-clinical (Barr et al., 2007) and clinical data (Oroszi and Goldman, 
2004; Ray and Hutchison, 2004; Bart et al., 2005) that describe a correlation 
between a functional polymorphism of the µ-opioid receptor gene (OPRM1) and
vulnerability for ethanol dependence. This polymorphism is also thought to be
related to the response to naltrexone in the treatment of alcoholics (Oslin et al., 
2003; Anton et al., 2006, 2008; Ray and Hutchison, 2007; Haile et al., 2008; 
Oroszi et al., 2008; Kim et al., 2009), though not all studies agree (Gelernter et 
al., 2007; Mitchell et al., 2007; Tidey et al., 2008). 
DOPAMINE IS INVOLVED IN THE MECHANISM OF DRUG REINFORCEMENT
There is a plethora of evidence suggesting that dopamine plays a role in drug 
reinforcement., including evidence that reinforcing drugs increase dopamine in 
the mesolimbic system (for reviews, see Wise and Bozarth, 1985; Leshner and 
Koob, 1999; Pierce and Kumaresan, 2006). It is important to note that reinforcing 
drugs also activate non-dopaminergic mechanisms (see Boutrel, 2008). For the 
purposes of this dissertation, however, we focus on dopamine. We will therefore 
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discuss dopamine, its role in general drug and ethanol reinforcement, and the 
mesolimbic dopaminergic system. 
Dopamine as a neurotransmitter
Discovery of dopamine, dopaminergic pathways and dopamine receptors
Dopamine was first synthesized in 1910 by George Barger and James Ewens, 
but it was not discovered in the brain until the 1950s by Arvid Carlsson and Nils-
Âke Hillarp (Montagu, 1957, Carlsson et al., 1958; Bertler and Rosengren, 1959).
Dopamine is a neurotransmitter in its own right, but is also a precursor of other 
neurotransmitters - norepinephrine and epinephrine. It was observed that 
dopamine was synthesized, stored, and released from neurons in the brain 
(Portig and Vogt, 1969; Vogt, 1973).
In the 1960s, a fluorescence histochemical method for the detection of 
catecholamine and indoleamine neurons and their pathways in the brain was 
developed and used to identify nigrostriatal and mesolimbic dopamine neuronal 
pathways (Dahlström & Fuxe, 1964; Andén et al., 1965, 1966). Since then other 
dopaminergic pathways have been identified. The dopaminergic pathways 
include the mesolimbic, mesocortical, nigrostriatal and tuberoinfundibular 
pathways. The mesolimbic pathway arises from the VTA and projects to 
structures in the ventral striatum including the NAc (Weiss and Porrino, 2002). 
The mesocortical pathway is closely associated with the mesolimbic pathway, 
and is the pathway from the ventral tegmental area (VTA) to the cortex. The 
nigrostriatal pathway is the pathway from the substantia nigra to the striatum. 
The tuberoinfundibular pathway is the pathway from the hypothalamus to the 
32
pituitary gland. The mesolimbic system is thought to be involved in natural 
reward and drug reinforcement.
Dopamine is synthesized from the amino acid tyrosine by tyrosine hydroxylase 
into DOPA (dihydroxyphenylalanine), which in turn is converted, via DOPA 
decarboxylase, into dopamine. Dopamine is metabolized as shown in Figure 1.6.
It was observed that dopamine stimulated adenylyl cyclase (Kebabian et al., 
1972). In the search for an anti-psychotic binding site in the brain, it was
(1) dopamine
(2) 3, 4-dihydroxyphenylacetaldehyde
(3) 3,4-dihydroxyphenylacetic acid (DOPAC)
(4) 3-methoxy, 4-hydroxyphenylethanamide (3-MT)
(5) 3-methoxy, 4-hydroxyphenylacetaldehyde
(6) 3-methoxy, 4-hydroxyphenylacetic acid (HVA)
MAO = monoamine oxidase, COMT = catechol-O-metyltransferase. Me = methyl.
Figure 1.6. Metabolism of dopamine. Figure adapted from images in McCoy et al. (2003). 
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discovered that dopamine and haloperidol bound to the same site (Seeman et 
al., 1976). Not long afterward, subtypes of the dopamine receptor, were 
discovered, and classified into D1 and D2 based on their pharmacology and 
coupling to adenylyl cyclase (Kebabian and Calne, 1979). Dopamine receptors, 
like opioid receptors, belong to the class of G-Protein Coupled Receptors. 
Activation of the D1 and D2 receptor led to the stimulation and inhibition of 
adenylyl cyclase, respectively. Since then, molecular biology and genetics 
enabled the discovery of more dopamine subtypes - D3, D4, and D5 (Strange, 
1991). These receptors are classified as either D1-like (D1, D5) or D2-like (D2, 
D3, and D4) based on their effect on adenylyl cyclase, with the D1 and D2-like 
dopamine receptors increasing and decreasing adenylyl cyclase, respectively. 
Dopamine receptors may form homooligomers such as D2-D2 (Lee et al., 2003) 
and heterooligomers such as D1-D2 (O’Dowd et al., 2005; George and O’Dowd, 
2007; Rashid et al., 2007; So et al., 2007). Dopamine receptors can also undergo 
physical interactions to form heterooligomers with other receptors such as NMDA 
(Zhang et al., 2009), adenosine A2A (Kamiya et al., 2003; Vidi et al., 2008), 
serotonin (Lee et al., 2000), cannabinoid CB1 (Kearn et al., 2005) and µ-opioid 
(Juhasz et al., 2008). The dopamine receptors are found widely in the brain and 
are well associated with the mesolimbic dopaminergic pathway (Jaber et al., 
1996). 
The role of dopamine in drug reinforcement
Dopamine is thought to play a significant role in drug reinforcement. However, 
the specific role of dopamine in drug reinforcement is still being debated, and 
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ideas about dopamine as a direct substrate for reward, and dopamine as a 
learning signal for reward prediction have been proposed.
Dopamine as a neurochemical correlate of reward
Wise and Bozarth (1987) introduced the psychomotor stimulant theory of 
addiction. It proposed that dopamine mediates general functions of locomotor 
activity, behavioral activation, and arousal. This idea is supported by numerous 
studies (Salamone et al., 1994; Redgrave et al., 1999; Salamone and Correa, 
2002). However, there are numerous problems associated with this hypothesis 
(Salamone et al., 2005). A major limitation of this hypothesis is that it is very 
general and does not address reward-specific aspects of dopamine activation. 
Many natural rewards and reinforcing drugs activate mesolimbic dopamine (for 
reviews, see Wise and Bozarth, 1985; Leshner and Koob, 1999; Pierce and 
Kumaresan, 2006), and also cause behavioral motivation. It is therefore very 
tempting to assume that dopamine directly relates to pleasure.
Wise (1978) proposed that dopamine activity is equal to reinforcement, and that 
dopamine signals are translated to pleasure, with the amount of dopamine being
equal to the amount of pleasure. In this regard, by extension, low dopamine or 
decreased dopamine increase following a stimulus would indicate that the 
stimulus was not pleasurable or had low hedonic value. However, after 6-
hydroxydopamine (6OHDA) depletion of mesolimbic dopamine, animals could 
still attribute some hedonic value to reinforcers (Berridge et al., 1989; Berridge 
and Robinson, 1998). Also, non-dopaminergic (dopamine knockout) and hyper-
dopaminergic (dopamine transporter knockout mice) states did not affect the 
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hedonic properties of reinforcers (Cannon and Palmiter, 2003; Peciña et al., 
2003; Cannon and Bseikri, 2004; Cagniard et al., 2006). ICSS increases 
dopamine in the shell and core of the NAc during the acquisition of lever press 
behavior to receive the ICSS, but after the behavior was established, dopamine 
release was not continued (Garris et al., 1999). In addition, stress and aversive 
conditions can also stimulate dopamine release (Abercrombie et al., 1989; 
Imperato et al., 1992a, b). Taking into account all the above evidence, the idea 
that dopamine release is directly correlated with reinforcement is doubted.
Dopamine as a prediction signal of reward
More recent ideas propose a role for dopamine in reward prediction and learning. 
Dopamine may act as a signal that encodes links between a reinforcing agent 
and associated stimuli (Di Chiara, 1995; Horvitz, 2000; Robinson and Berridge, 
2000). For instance, Di Chiara (2002) proposed that a primary function of 
dopamine is to associate reward produced by the reinforcing substance and the 
environment stimuli that were present at the time the reward experience occurred 
(Di Chiara, 2002). The dopamine response that occurs enables a link to be 
formed between the rewarding effect of the drug and the environment or context 
in which the drug is taken. However a limitation of this idea is that there is 
evidence that associative learning can occur in animals with dopamine depletion 
(Berridge and Robinson, 1998).
Dopamine is thought to be involved in signaling reward prediction errors 
(Mirenowicz and Schultz, 1994; Schultz, 1997, 1998; Schultz et al., 1997; 
Hollerman and Schultz, 1998; Wise, 2004). For example, if there is conditioned 
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stimulus that signals an impending reward, the presentation of the reward has 
been correctly predicted and there is no prediction error and therefore no 
increase in dopamine firing pattern. However, if there is an unexpected reward, 
there is an increase in the firing pattern of dopaminergic neurons. Overall, 
dopamine integrates the process of learning about the reward, such that 
environmental stimuli associated with the reward can predict future cases of 
reward presentation (de la Fuente-Fernandez et al., 2002; Fiorillo et al., 2003; 
Tobler et al., 2003, 2005). There is some evidence that dopamine neurons adjust 
their firing after the prediction of reward is learned (Schultz et al., 1997). It has 
also been suggested that dopamine neurons may not code reward learning or 
cause any new learning themselves, but may instead be activated as a 
consequence of learning signals (reflecting learning and prediction) that are 
generated elsewhere in the brain (Berridge, 2007). Robinson and Berridge 
(1993) proposed that dopamine attributes incentive salience to stimuli associated 
with dopamine release, making those events salient and significant. In other 
words, dopamine may amplify the perception of, and response to, a reward 
associated stimulus. In this way, dopamine may turn prediction for reward into 
motivation or incentive, strengthening drug seeking behavior.
The role of dopamine in the mechanism of ethanol reinforcement
In previous sections, we classified ethanol as a reinforcing drug. In the last 
section, we discussed a role for dopamine in the mechanism of general drug
reinforcement. It is important to discuss a role for dopamine in the specific 
mechanism of ethanol reinforcement. Mesolimbic dopamine is thought to be 
involved in ethanol reinforcement (for review, see Gonzales et al., 2004). Ethanol 
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increases NAc dopamine during ethanol self-administration (Weiss et al., 1992, 
1993; Samson et al., 1993). Just as ethanol administration causes an increase in 
mesolimbic dopamine, ethanol withdrawal causes a decrease in dopamine 
release in the NAc (Rossetti et al., 1992; Diana et al., 1993). Systemic dopamine 
antagonists and agonists alter ethanol self-administration (Pfeffer and Samson, 
1988; Hodge et al., 1992; Rassnick et al., 1992; Samson et al., 1992, 1993; 
Slawecki et al., 1997). Furthermore, administration into the NAc and VTA of a 
dopamine D2 antagonist and a D2/D3 agonist dose-dependently suppressed 
ethanol self-administation (Samson and Hodge, 1993). Also, dopamine D1 and 
D2 antagonists suppress ethanol-seeking behavior (Czachowski et al., 2001; Liu 
and Weiss, 2002). Intra-NAc administration of fluphenazine, a dopamine receptor 
antagonist, suppressed conditioned place preference due to 
intracerebroventricular ethanol administration in rats (Walker and Ettenberg, 
2007). Using genetic knockout models, D1 and D2 knockout mice elicited a 
decrease in ethanol consumption (El-Ghundi et al., 1998; Phillips et al., 1998). 
Furthermore, dopamine D2 receptor over-expression in the NAc led to a 
decrease in drinking behavior (Thanos et al., 2001). Low basal activity in the 
mesolimbic system is thought to be an important factor in determining increased 
ethanol preference (George et al., 1995).
However, 6-OHDA lesions of the mesolimbic pathway caused variable effects on 
ethanol self-administration including no change, decrease or increase responding 
for ethanol in the operant self-administration paradigm in rats (Myers and 
Melchior, 1975; Brown and Amit, 1977; Quarfordt et al., 1991; Rassnick et al., 
1993; Ikemoto et al., 1997; Koistinen et al., 2001). It is suggested that ethanol-
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seeking behavior cannot be learned without intact mesolimbic dopamine. 
However, dopamine may not be as important in ethanol reinforcement once the 
behavior is learned. 
The dopamine response in the NAc may not be a pharmacological effect of 
ethanol. For example, after repeated ethanol injections, a saline injection also 
caused NAc dopamine release (Philpot and Kirstein, 1998). Also, in the operant 
self-administration paradigm, animals anticipating access to ethanol (during 
waiting period) and during self-administration had an increase in dopamine in the 
NAc (Weiss et al., 1992, 1993, 1996; Gonzales and Weiss, 1998; Melendez et 
al., 2002). These data suggest that the conditioned stimuli associated with 
ethanol are able to promote NAc dopamine release. There is also the idea that it 
is the novelty of the ethanol experience that causes an increase in mesolimbic 
dopamine (Nurmi et al., 1996). The dopamine response may also be dependent 
on the strain of rat used. For instance, there is data showing that in ethanol-
preferring (P) rats, compared to Wister rats, there is an increase in dopamine 
release in the NAc in anticipation of ethanol (Katner et al., 1996).
THE ENDOGENOUS OPIOID PEPTIDES AND THE µ-OPIOID RECEPTORS 
INTERACT WITH THE MESOLIMBIC DOPAMINERGIC PATHWAY
We have discussed dopamine and its proposed role in ethanol reinforcement, 
and we introduced the mesolimbic pathway which is thought to be one of the 
major reward pathways in the brain. In previous sections, we discussed that the 
endogenous opioid peptides and the µ-opioid receptors are involved in ethanol 
reinforcement. Do dopamine and the endogenous opioid systems interact 
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together to contribute to the mechanism of ethanol reinforcement? It is therefore 
important to discuss any interactions between the endogenous opioid peptides, 
the µ-opioid receptors and the mesolimbic dopaminergic pathway.
As mentioned before, the mesolimbic dopaminergic neurons arise from the VTA 
and project to structures within the ventral striatum, including the NAc (Weiss & 
Porrino, 2002). The VTA sends dopaminergic and GABAergic projections to the 
NAc (Van Bockstaele and Pickel, 1995). The NAc is subdivided into core and 
shell regions (Meredith, 1999; Zahm, 1999). The NAc shell (NAcS) sends 
GABAergic projections to the VTA (Walaas and Fonnum, 1980; Heimer et al., 
1991; Kalivas et al., 1993). VTA dopaminergic neurons are influenced by 
afferents expressing a variety of neurotransmitters and neuromodulators (for 
review, see Kalivas, 1993). Subsets of mesolimbic dopaminergic neurons co-
localize and co-release the highly selective δ-opioid peptide [D-Ala2] deltorphin I 
(Dupin et al., 1991; Tooyama et al., 1993; Casini et al., 2004), and [D-Ala2] 
deltorphin I binding sites have been found in the NAc (Gouarderes et al., 1993; 
Renda et al., 1993). More research needs to be done to determine the interaction 
between [D-Ala2] deltorphin I and the mesolimbic dopaminergic system.
Interactions with the mesolimbic dopaminergic pathway have been established
for some of the other endogenous opioid peptides listed in Table 1.2.
Neuroanatomical interactions
Localization of endogenous opioid peptides
The endogenous opioid peptides are located in neurons that interact with the 
mesolimbic dopaminergic pathway. The opioid precursors (POMC, 
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proenkephalin, and prodynorphin), opioid peptides (β-endorphin, enkephalin,
dynorphin and endomorphin) and opioid receptors have unique anatomical 
distributions throughout the CNS (Watson et al., 1982a; Akil et al., 1984; Martin-
Schild et al., 1999). In the brain, POMC is synthesized in the arcuate nucleus of 
the hypothalamus and in the nucleus tractus solitarius (Bloom et al., 1978; Finley 
et al., 1981a), with widespread projections from these sites throughout the brain. 
β-endorphin containing fibers from the arcuate nucleus of the mediobasal 
hypothalamus project to the limbic structures such as the NAc (Khachaturian et 
al., 1984). There is no evidence that β-endorphin containing fibers from the 
arcuate nucleus of the mediobasal hypothalamus project to the VTA 
(Khachaturian and Watson, 1982), and β-endorphin immunoreactivity is very 
sparse in the VTA (Khachaturian and Watson, 1982; Khachaturian et al., 1984). 
Interestingly, apart from the arcuate nucleus and the nucleus tractus solitarius, 
low levels of POMC mRNA (previously undetected) have been found in the VTA 
and NAc (Leriche et al., 2007) and amygdala (Civelli et al., 1982), suggesting 
that β-endorphin can be synthesized in these regions also. Also, there is a 
convergence of β-endorphin and enkephalin terminal fibers in the NAc and 
central nucleus of the amygdala (Finley et al., 1981a, b), suggesting that the
opioid peptides may interact with each other. Apart from β-endorphin, POMC is 
also processed to other endorphins (α- and γ-endorphins), adrenocorticotrophic 
hormone and β- and γ-melanocyte stimulating hormone. In the arcuate nucleus 
of the hypothalamus, β-endorphin can be co-localized in neurons with GABAergic 
(Collin et al., 2003; Hentges et al., 2004), glutamatergic (Collin et al., 2003; Kiss 
et al., 2005) and cholinergic (Meister et al., 2006; Maolood and Meister, 2008) 
phenotypes. These neurons project to extra-hypothalamic sites. For example, 
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some β-endorphin-containing GABAergic neurons are found in the central 
nucleus of the amygdala (Oertel et al., 1983). Presently, the phenotype(s) of β-
endorphin neurons projecting to the NAc are unknown.
Proenkephalin gene encodes a protein which is processed to four copies of met-
enkephalin, one copy of leu-enkephalin, and one copy each of two extended met-
enkephalin sequences (met-enkephalin-arg-gly-leu and met-enkephalin-arg-phe)
(Gubler et al., 1982). Enkephalin containing neurons are found widely distributed 
throughout the brain and comprise local circuits and long projecting neurons. 
Enkephalin containing neurons are found in dopaminergic pathways in the 
substantia nigra, and the dorsal and ventral striatum (Sar et al., 1978; Johnson et 
al., 1980; Fallon and Leslie, 1986). Proenkephalin mRNA is found in the NAc 
(Bloch et al., 1986; Harlan et al., 1987; Curran and Watson, 1995). Also, there is 
evidence of enkephalin synthesizing cells in the VTA (Finley et al., 1981b; Harlan 
et al., 1987). There are moderate levels of enkephalin immunoreactivity in the 
VTA (Sar et al., 1978; Johnson et al., 1980; Wamsley et al., 1980a, b; 
Khachaturian et al., 1983a, b; Garzón and Pickel, 2002), whereas there are 
significant levels of enkephalin in the NAc (Wamsley et al., 1980a, b; 
Khachaturian et al., 1983a, b). In addition there are enkephalinergic neurons in 
structures associated with the mesolimbic pathway such as the amygdala, 
hippocampus, raphe nuclei amongst others (Khachaturian et al., 1983a, b). 
Enkephalins are co-localized in some GABAergic neurons (Kalivas et al., 1993; 
Sesack and Pickel, 1995). Enkephalin-containing neurons project from structures 
including the NAcS and ventral pallidum to the VTA (Kalivas et al., 1993). 
However, it is important to add that enkephalin is contained in only about 3% of 
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the neurons projecting from the NAcS to the VTA (Kalivas et al., 1993; Lu et al., 
1998). In the VTA, 50-60% of the enkephalin containing terminals directly form 
synapses with the dopaminergic neurons, while the rest formed synapses with 
non-dopaminergic neurons (Sesack and Pickel, 1992).
Prodynorphin gives rise to α-neoendorphin, β-neoendorphin, dynorphin A, 
dynorphin A (1-8), dynorphin B, and leumorphin (Civelli et al., 1985). Dynorphin 
immunoreactivity is found widely distributed throughout the brain (Ghazarossian 
et al., 1980; Goldstein and Ghazarossian, 1980; Hollt et al., 1980; Gramsch et 
al., 1982; Khachaturian et al., 1982; Watson et al., 1982a, b; Cone et al., 1983). 
The hypothalamus contains a high density of dynorphin-immunoreactive cell 
bodies (Khachaturian et al., 1982; Vincent et al., 1982; Roth et al., 1983; Weber 
and Barchas, 1983; Fallon et al., 1985). There are also dynorphin 
immunoreactive cell bodies in structures associated with the mesolimbic pathway 
such as the central nucleus of the amygdala (Weber and Barchas, 1983; Fallon 
et al., 1985) and hippocampal formation (Khachaturian et al., 1982). There are 
high densities of dynorphin immunoreactive fibers and terminals in regions such 
as the substantia nigra, hypothalamus, hippocampal formation, ventral pallidum 
(Khachaturian et al., 1982; Vincent et al., 1982; Weber and Barchas, 1983; 
Fallon et al., 1985). Preprodynorphin mRNA is found in GABAergic medium spiny 
neurons in the NAc, suggesting that many dynorphin producing neurons are 
found resident in the NAc (Mansour et al., 1994b; Curran and Watson, 1995; 
Furuta et al., 2002).This is confirmed by observations showing that the NAc 
contains moderate densities of dynorphin immunoreactivity (Khachaturian et al., 
1982; Vincent et al., 1982; Weber and Barchas, 1983; Fallon et al., 1985). There 
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is moderate dynorphin immunoreactivity in the VTA (Pickel et al., 1993; Fallon et 
al., 1985). Within the VTA, approximately 22%, 17% and 60% of dynorphin 
immunoreactive terminals form synapses with dopaminergic, non-dopaminergic 
and astrocytic targets, respectively (Pickel et al., 1993). As mentioned before, the 
NAcS sends projections to the VTA (Heimer et al., 1991; Kalivas et al., 1993; 
Zahm and Heimer, 1993; Lu et al., 1998; Usuda et al., 1998; Zahm et al., 1999, 
2001). Unlike for enkephalin (see discussion above), almost all neurons 
projecting from the NAcS to the VTA contain dynorphin (Zhou et al., 2003). Also, 
dynorphin afferents from the amygdala and hypothalamus project to the VTA 
(Fallon et al., 1985). With regard to the hypothalamus, dynorphin is contained 
almost all hypothalamic orexinergic neurons (Chou et al., 2001) which are of a 
glutamatergic phenotype, and which form synapses with dopaminergic and non-
dopaminergic cells (GABA) in the VTA (Balcita-Pedicino and Sesack, 2007).
Cell bodies of endomorphin-1 and endomorphin-2- containing neurons are found 
in the hypothalamus (Martin-Schild et al., 1999; Zadina et al., 1999; Pierce and 
Wessendorf, 2000; Greenwell et al., 2002, 2007), especially in the periventricular 
nucleus, between the dorsomedial and ventromedial hypothalamus and between 
the ventromedial and arcuate nuclei of the hypothalamus (Greenwell et al., 
2002). From the hypothalamus, endomorphin containing neurons project to the 
VTA (Pierce and Wessendorf, 2000; Greenwell et al., 2002) and to the NAc 
(Schreff et al., 1998; Martin-Schild et al., 1999; Whitten et al., 2001). 
Endomorphin immunoreactive fibers are also seen in structures associated with 
the mesolimbic pathway such as the raphe nucleus, laterodorsal tegmental 
nucleus, and the amygdala (Pierce and Wessendorf, 2000).
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Localization of the µ-opioid receptors
Opioid receptors are widely distributed in the CNS and are found in the 
mesolimbic pathway (Quirion et al., 1983; Mansour et al., 1988, 1993; 1994a; 
1995a, b, c, d). The different opioid receptors have distinct distributions (Mansour 
et al., 1987; Tempel and Zukin, 1987). µ-opioid receptors are found in the 
striatum, cortex, hippocampus, amygdala, raphe nuclei, and thalamic nuclei, 
amongst others (Mansour et al., 1987, 1994a, c; Tempel and Zukin, 1987). µ-
opioid receptors have moderate density in the VTA (Mansour et al., 1987, 1995a, 
b, c; German et al., 1993; Moriwaki et al., 1996; Garzón and Pickel, 2001, 2002). 
Within the VTA, most µ-opioid receptors are found on non-dopaminergic neurons 
(though some dopaminergic neurons express µ-opioid receptors) (Dilts and 
Kalivas, 1989; Garzón and Pickel, 2001). There is a significant density of µ-opioid 
receptors in the NAc (Quirion et al., 1983; Moriwaki et al., 1996; Svingos et al., 
1996). The µ-opioid receptor is predominantly located extrasynaptically on 
dendrites and spines of the GABAergic medium spiny neurons of the NAc, or 
their targets (Svingos et al., 1996, 1997). There are very few µ-opioid receptors 
on dopaminergic terminals in the NAc (Unterwald et al., 1989).
We have discussed literature showing that µ-opioid receptors are predominantly 
located on non-dopaminergic neurons in the mesolimbic pathway. Also, we have 
talked about the neuroanatomical interaction between β-endorphin, enkephalin, 
dynorphin, endomorphin, the µ-opioid receptor and the mesolimbic pathway. A 
summarized illustration of the mesolimbic dopaminergic pathway and associated 
endogenous opioid system is shown in Figure. 1.7.
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Figure 1.7. Hypothetical neuroanatomical interactions between endogenous opioid 
peptides, the µ-opioid receptors and the mesolimbic dopaminergic pathway. VTA = 
ventral tegmental area, NAc = nucleus accumbens. Author’s concept of cited literature.
Neuropharmacological interactions
β-endorphin, enkephalin, and endomorphin increase mesolimbic dopamine 
release
With evidence of neuroanatomical interactions between opioid peptides and 
receptors and the mesolimbic dopaminergic pathway (see Figure 1.7), there is a 
high probability that endogenous opioid peptides regulate mesolimbic dopamine. 
This indeed is the case (see Van Ree et al., 1999). The regulation of VTA 
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dopamine neurons by opioids is not direct. For instance, VTA dopaminergic 
neurons do not respond to direct application of enkephalin (Johnson and North, 
1992), though not all studies agree (Ford et al., 2006). For example, while 
Johnson and North (1992) did not find any responses by VTA dopamine neurons 
to enkephalin, Ford et al. (2006) found that enkephalin directly inhibits the firing 
rates of about 40% of the VTA dopaminergic neurons that project to the NAc.
β-endorphin, enkephalin, and endomorphin, which all have efficacy at µ-opioid 
receptors, increase mesolimbic dopamine release. For example, β-endorphin 
increases mesolimbic dopaminergic neuronal activity (Stinus et al., 1980), and 
dopamine activity and release in the NAc (Iyenger et al., 1989; Spanagel et al., 
1990a, 1991a, b). Also, administration of β-endorphin onto VTA dopamine cells 
in vitro increased dopamine neuron firing (Trulson and Arasteh, 1985). In 
addition, locally administered β-endorphin increases dopamine release in the 
NAc (Iyenger et al., 1989). Intracerebroventricularly administered β-endorphin 
activates the NAc and other associated limbic regions such as the lateral septal 
nucleus, the amygdalo-hippocampal transition area and the hippocampal 
formation (Ableitner and Schulz, 1992). Interestingly, data from Ableitner and 
Schulz (1992) suggests that the NAc, but not the VTA, is activated by 
intracerebroventricularly administered β-endorphin. This is buttressed by data 
showing that β-endorphin innervation of the VTA is very negligible compared to 
the NAc (Khachaturian and Watson, 1982; Khachaturian et al., 1984).
Enkephalins increase dopamine in the NAc (Cador et al., 1989). Intra-VTA 
administration of thiorphan, an enkephalinase inhibitor, increases dopamine 
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release in the NAc, suggesting that mesolimbic dopamine is regulated by an 
endogenous opioid tone and enkephalin contributes significantly to this. This also 
shows that endogenous enkephalins activate the dopaminergic activity in the 
VTA (Kalivas and Richardson-Carlson, 1986; Dauge et al., 1992). Intra-VTA 
administration of endomorphin-1 increases dopamine in the NAc (Terashvili et 
al., 2008). Intracerebroventricular administration of endomorphin-2 increases 
dopamine in the shell of the NAc (Huang et al., 2004). Also, endomorphins-1 and 
-2, when administered locally, increase dopamine in the NAc (Okutsu et al., 
2006; Aono et al., 2008; Saigusa et al., 2008).
These findings suggest that there is an endogenous opioid-mediated modulation 
of dopamine release. We have just discussed that endogenous opioid peptides 
can increase mesolimbic dopamine. We also show that the endogenous peptides 
(β-endorphin, enkephalin, endomorphin) that can increase mesolimbic dopamine 
release have some efficacy at the µ-opioid receptors. It is important, therefore, to 
discuss the µ-opioid receptors and how they affect mesolimbic dopamine release 
when activated. An important question to ask is this: Does activation of the µ-
opioid receptor lead to an increase in mesolimbic dopamine?
Activation of µ-opioid receptors increases mesolimbic dopamine release
Activation of µ-opioid receptors increases mesolimbic dopamine release. 
Morphine, which has high affinity and efficacy at the µ-opioid receptor (Raynor et 
al., 1994), increases mesolimbic dopamine activity and release (Di Chiara and 
Imperato, 1988b; Leone et al., 1991; Pothos et al., 1991; Rada et al., 1991; 
Wood and Rao, 1991; Pontieri et al., 1995; Borg and Taylor, 1997; Piepponen et 
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al., 1999; Hamilton et al., 2000; Melis et al., 2000). This morphine-evoked 
increase in dopamine release is due predominantly to activation of the µ-opioid 
receptor. This is supported by evidence showing that morphine-evoked increases 
in mesolimbic dopamine release were abolished in µ-opioid receptor, and not δ-
opioid receptor, knockout mice (Chefer et al., 2003). Furthermore, blockade of 
the δ-opioid receptors did not attenuate dopamine release in the NAc due to 
systemically administered morphine (Borg and Taylor, 1997).
Studies with other selective µ-opioid agonists reinforce the observation that 
activation of µ-opioid receptors increases mesolimbic dopamine activity and
release. For example, DAMGO, a highly selective µ-opioid agonist (Emmerson et 
al., 1994), when administered intracerebroventricularly, caused an increase in 
dopamine levels in the NAc (Spanagel et al., 1990b), and this effect is blocked by 
the selective µ-opioid receptor antagonist: D-Pen-Cys-Tyr-D-Trp-Orn-Thr-Pen-
Thr-NH2 (CTOP). Activation of the µ-opioid receptors in the VTA leads to an 
increase in dopamine release in the NAc. For instance, administration of DAMGO 
into the VTA caused an increase in dopaminergic neuron firing activity (Noel and 
Gratton, 1995) and dopamine release in the NAc (Spanagel et al., 1992; Devine 
et al., 1993b). Furthermore, systemic administration of naloxonazine, a µ1-opioid 
antagonist, suppressed the increase in dopamine metabolism in the NAc due to 
intra-VTA DAMGO (Latimer et al., 1987). Activation of µ-opioid receptors in 
numerous neuroanatomical structures associated with the mesolimbic 
dopaminergic pathway can lead to an increase in dopamine release in the NAc 
(see Table 1.7).
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Table 1.7. Neuroanatomical structures in which activation of the µ-opioid receptor leads 
to increases in dopamine in the nucleus accumbens.
Neuroanatomical structure(s) Selected reference(s)
Globus pallidus Anagnostakis and Spyraki, 1994
Mediobasal thalamus Klitenick and Kalivas, 1994
Nucleus accumbens Yoshida et al., 1999; Hirose et al., 
2005; Okutsu et al., 2006
Pedunculopontine tegmental nucleus Klitenick and Kalivas, 1994
Raphe nucleus Klitenick and Wirtshafter, 1995
Ventral tegmental area Spanagel et al., 1992; Devine et al., 
1993b
However, some studies show an increase in NAc dopamine levels with VTA 
microinjection of µ-opioid receptor antagonists (Devine et al. 1993c) suggesting 
an intrinsic non-opioid effect of CTOP on neurons (Chieng et al., 1996) or 
perhaps a more complex VTA circuitry. µ-opioid receptor agonists are thought to 
increase NAc dopamine by hyperpolarizing (and thus inhibiting) inhibitory 
GABAergic interneurons/afferents in the VTA (Johnson and North, 1992).
It is still controversial whether local µ-opioid receptor activation in the NAc 
causes an increase in NAc dopamine release. However, the evidence seems to 
suggest that µ-opioid receptor activation in the NAc has both a dopaminergic and 
non-dopaminergic component. For instance, even though some studies have 
shown that µ-opioid receptor activation in the NAc did not increase NAc 
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dopamine activity (Longoni et al., 1991; Pentney and Gratton, 1991; Spanagel et 
al., 1992), others show that µ-opioid receptor activation in the NAc caused an 
increase in NAc dopamine release (Yoshida et al., 1999; Hirose et al., 2005; 
Okutsu et al., 2006; Aono et al., 2008; Saisusa et al., 2008). Though it is not well 
understood, one possible explanation for the dopamine-dependent and 
dopamine-independent effects of intra-NAc µ-opioid receptors can be done by 
taking the heterogeneity of the NAc into consideration. In this light, it can be said 
that there is a percentage of NAc µ-opioid receptors that when activated will lead 
to an increase in dopamine release in the NAc. The differences in between 
dopamine-responsive and non-responsive µ-opioid receptors could be due to the 
region of the NAc in which these receptors are expressed. The regional 
differences in µ-opioid receptor-driven dopamine response is supported by 
immunohistochemical data showing 14% more µ-opioid receptor in the shell than 
in the core of the NAc (Pickel et al., 2004), and pharmacological data showing 
that local administration of DAMGO increased, decreased or had no effect on 
NAc dopamine release in the core, shell, and core/shell overlap zones,
respectively (Hipolito et al., 2008). 
Mesolimbic dopamine can also be increased by activation of µ-opioid receptors 
that interact with δ-opioid receptors. For example, DPDPE, administered 
intracerebroventricularly, caused an increase in dopamine levels in the NAc 
(Spanagel et al., 1990a; Manzanares et al., 1993), and this effect is blocked by 
the selective δ-opioid receptor antagonists: ICI 174,864 and naltrindole. 
Administration of DPDPE into the raphe nucleus also led to an increase in 
dopamine release in the NAc (Klitenick and Wirtshafter, 1995). Additionally, intra-
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VTA administration of DPDPE caused an increase in NAc dopamine release 
(Devine et al., 1993a, b), and this increase was attenuated by naltrindole, a 
selective δ-opioid receptor antagonist. This suggests that in the VTA, for 
instance, δ-opioid receptors are involved in mesolimbic dopamine release. 
However, on closer examination of the data, the concentrations (in the VTA) of 
DPDPE were 100-1000 fold higher than the concentrations of DAMGO (selective 
µ-opioid receptor agonist) required to cause this NAc dopamine increase (Devine 
et al., 1993b). An interpretation is that in the VTA, the δ-opioid receptors are 
simply less sensitive than the µ-opioid receptors in the mechanism of mesolimbic 
dopamine release. However, there is in vitro data that shows that VTA neurons 
are insensitive to DPDPE (Johnson and North, 1992) but not to DAMGO. The 
increase in mesolimbic dopamine release due to DPDPE can be accounted for 
by the idea of the δ-opioid recruitment of µ-opioid receptor mechanisms. In this 
idea, DPDPE may occupy δ-opioid receptors that are involved in some form of 
interaction with the µ-opioid receptors to lead to an increase in dopamine (see 
Figure 1.3, section on opioid receptor interactions). 
Locally applied DPDPE increases dopamine release in the NAc. This is also 
thought to be through the δ-opioid receptor (Pentney and Gratton, 1991; 
Manzanares et al., 1993; Suzuki et al., 1997). However, the increase in NAc 
dopamine through direct δ-opioid receptor activation is still very controversial. For 
example, systemic administration of non-peptidic selective δ-opioid receptor 
agonists:BW373U86 ((±)-[1(S*),2α,5β]-4-[[2,5-Dimethyl-4-(2-propenyl)-1-
piperazinyl](3-hydroxyphenyl)methyl]-N,N-diethylbenzamide dihydrobromide) and 
SNC 80 ((+)-4-[(αR)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-
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methoxybenzyl]-N,N-diethylbenzamide), failed to modify extracellular dopamine 
in the NAc (Longoni et al., 1998). Hirose et al. (2005) determined that a 
combined activation of both δ- and µ-opioid receptors in the NAc is required to 
cause an opioid-mediated increase in extracellular dopamine in the NAc. 
Furthermore, intra-NAc DPDPE-induced dopamine release in the NAc was 
partially attenuated by CTOP (Hirose et al., 2005). As we discussed above (see 
Figure 1.3, section on opioid receptor interactions), DPDPE is able to recruit µ-
opioid receptors, through the µ-δ-opioid receptor complex or through crosstalk
(Traynor and Elliot, 1993). Similarly, β-endorphin is thought to increase dopamine 
release in the NAc through µ-δ-opioid receptor interaction (Spanagel et al., 
1990a). Enkephalins can also act through µ-δ-opioid receptor interaction (George 
et al., 2000). In summary, activation of µ-opioid receptors, directly or through µ-δ-
opioid receptor interactions, can lead to an increase in NAc dopamine release.
We summarize this chapter as follows:
(1) Ethanol dependence is managed with naltrexone, a non-selective opioid 
antagonist. The involvement of the endogenous opioid systems in ethanol 
reinforcement is well supported by scientific evidence.
(2) Of the opioid receptors, the µ-opioid receptors play a major role in ethanol 
reinforcement.
(3) The mesolimbic dopamine plays a role in ethanol reinforcement.
(4) Endogenous opioid peptides activate µ-opioid receptors to increase 
mesolimbic dopamine release.
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Chapter 2. Rationale and Specific Aims
ETHANOL STIMULATES THE RELEASE OF MESOLIMBIC DOPAMINE 
Ethanol administration increases VTA dopamine neuron firing (Gessa et al., 
1985; Brodie et al., 1990, 1999) and NAc dopamine release (Imperato and Di 
Chiara, 1986; Di Chiara and Imperato, 1988a; Yoshimoto et al., 1991, 1992a, b; 
Blanchard et al., 1993; Blomqvist et al., 1993; Heidbreder and De Witte, 1993; 
Campbell and McBride, 1995; Yim et al., 1998; Yim and Gonzales, 2000; Boileau 
et al., 2003). Also, ethanol increases NAc dopamine release dose-dependently 
when administered locally into NAc (Wozniak et al., 1991; Yim et al., 1998; 
Tuomainen et al., 2003). Due to the high concentrations required to evoke 
dopamine release in the NAc, the systemic effect of ethanol on NAc dopamine is 
probably due to an action at some other sites, including the VTA (Samson et al., 
1997; Yim et al., 1998). 
Mechanisms of ethanol-stimulated mesolimbic dopamine release
Direct mechanisms
Ethanol directly activates VTA dopamine neurons (Brodie and Appel, 1998; 
Brodie et al., 1990, 1999). This could be due to ethanol-mediated inhibition of 
potassium currents (Appel et al., 2003), and voltage-gated potassium currents 
(m-currents) (Koyama et al., 2007). Also, ethanol targets the hyperpolarization-
activated cation current (Ih) to increase mesolimbic dopamine neuron firing 
(Okamoto et al., 2006). It is important to mention that in this direct mechanism, 
ethanol increases VTA neuron firing, but this may not necessarily translate to 
enhanced dopamine release in the NAc.
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Other mechanisms
Ethanol may recruit other neurochemical mechanisms in addition to the direct 
excitatory effects on VTA dopaminergic neurons. For example, serotonin 
potentiates ethanol-induced direct excitation of VTA dopaminergic neurons 
(Brodie et al., 1995). This could be due to ethanol stimulating serotonin 5-HT3 
receptors directly (Lovinger, 1991a, b; Davies et al., 2006) and enhancing the 
depolarizing effects of serotonin at the 5-HT3 receptor (Lovinger and White, 
1991). The 5-HT3 receptor is involved in ethanol-stimulated mesolimbic 
dopamine activity and release. For instance, local perfusion of a 5-HT3 
antagonist blocked ethanol-induced increases in somatodendritic dopamine in 
the VTA (Campbell et al., 1996; Liu et al., 2006). Furthermore, systemic 5-HT3 
blockade attenuates ethanol-induced dopamine release in the NAc (Carboni et 
al., 1989; Wozniak et al., 1990). Apart from 5-HT3 receptors, other 5-HT 
receptors are involved in the modulation of mesolimbic dopamine release. For 
example, nefazodone, a combined 5-HT2A antagonist and 5-HT reuptake 
inhibitor, decreases ethanol-stimulated NAc dopamine release (Olausson et al., 
1998).
Apart from the serotonergic system, other neurochemical mechanisms such as 
cholinergic, cannabinoid and glycinergic (just to mention a few), play a role in 
ethanol-stimulated mesolimbic dopamine release. For instance, the systemic and 
intra-VTA administration of mecamylamine, a nicotinic acetylcholine receptor 
(nAChR) antagonist, attenuated ethanol-evoked dopamine release in the NAc 
(Blomqvist et al., 1993, 1997; Ericson et al., 1998, 2003, 2008; Larsson et al., 
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2002, 2004). Cannabinoid CB1 receptor blockade inhibited ethanol-evoked 
stimulation of VTA neuron firing rate (Perra et al., 2005), and  other supporting 
studies show that ethanol-evoked mesolimbic dopamine release involves
cannabinoid mechanisms (Hungund et al., 2003; Cheer et al., 2007). Ethanol can 
also stimulate mesolimbic dopamine through mechanisms involving the glycine 
receptor (Molander and Söderpalm, 2005, Molander et al. 2005). Also, there is 
some evidence (though not conclusive) for opioid mechanisms of ethanol-
stimulated mesolimbic dopamine release (Acquas et al., 1993; Benjamin et al., 
1993; Tanda and Di Chiara, 1998; Job et al., 2007). Now, we have introduced the 
possibility of the involvement of opioids (in addition to other non-opioid systems) 
in the mechanism of ethanol-stimulated mesolimbic dopamine release. In the 
previous chapter, we discussed the idea that endogenous opioids activate the µ-
opioid receptor to modulate mesolimbic dopamine release. Ethanol may be 
changing the endogenous opioid system, such that this change leads an 
increase in mesolimbic dopamine activity. To understand this, it is important to 
discuss of how ethanol interacts with endogenous opioid system.
ETHANOL ALTERS ENDOGENOUS OPIOID ACTIVITY
Ethanol stimulates endogenous morphine-like alkaloids
Almost 40 years ago, it was suggested that ethanol may be metabolized in the 
body to ultimately give rise to the formation of morphine-like alkaloids called 
tetrahydroisoquinolines (TIQ) (Davis and Walsh, 1970a, b, Davis et al., 1970; 
Walsh et al., 1970; Yamanaka et al., 1970). Alcohol is metabolized by alcohol 
dehydrogenase to acetaldehyde. Dopamine is metabolized by monoamine 
oxidase to 3, 4-dihydroxyphenylacetaldehyde (refer to Figure 1.6). It is postulated 
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that acetaldehyde competitively inhibits the metabolism of 3, 4-
dihydroxyphenylacetaldehyde to 3, 4-dihydroxyphenylacetic acid (DOPAC) by 
competing for acetaldehyde dehydrogenase, and the 3, 4-
dihydroxyphenylacetaldehyde reacts with dopamine to give rise to 
tetrahydropapaveroline (THP) (Figure 2.1) (Haber et al., 1997). 
(1) dopamine
(2) 3, 4-dihydroxyphenylacetaldehyde
(3) 3, 4-dihydroxyphenylacetic acid (DOPAC)
(4) tetrahydropapaveroline (THP)
Figure 2.1. Schematic showing the mechanism of formation of the opioid-like 
tetrahydropapaveroline (THP). CH3CH2OH = ethanol, CH3CHO = acetaldehyde. Figure 
adapted from Haber et al. (1997).
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Acute ethanol increases THP levels in the striatum and midbrain (Cashaw, 
1993). However, a limitation of this study is that rats were decapitated and tissue 
extracted to measure THP levels 100 min after intraperitoneal ethanol 
administration. It is therefore not clear from this study that ethanol increases 
THPs. THPs affect dopamine kinetics in the NAc (Melchior et al., 1978), but it is 
not clear if this effect is with regards to dopamine release or dopamine re-uptake.
Extensive research has been done on 1-methyl-6, 7-dihydroxy-1, 2, 3, 4-
tetrahydroisoquinoline (salsolinol) (Figure. 2.2) (Jamal et al., 2003a, b). Salsolinol 
is formed from the condensation of dopamine and acetaldehyde (Collins and 
Bigdeli, 1975; Haber et al., 1997). 
(1) dopamine
(2) salsolinol
Figure 2.2. Schematic showing the mechanism of formation of salsolinol. CH3CH2OH = 
ethanol, CH3CHO = acetaldehyde. Figure adapted from Haber et al. (1997).
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Salsolinol is found in the plasma and urine of humans after consuming ethanol 
(Collins et al., 1979), and is lower in the brain, at autopsy, of abstinent alcoholics 
than in non-abstinent alcoholics (Sjörquist et al., 1983). Salsolinol displaces met-
enkephalin from its binding sites (Lucchi et al., 1982, 1985), and probably acts at 
µ-opioid receptors (Lucchi et al., 1985). Furthermore, salsolinol is reinforcing in 
the VTA (Rodd et al., 2008), suggesting that salsolinol may activate the 
mesolimbic dopaminergic system. However Matsubawa et al. (1987) found no 
correlation between blood ethanol and brain salsolinol and dopamine levels in 
rats. Some data shows that chronic, but not acute alcohol leads to an increase in 
salsolinol in dopamine rich areas of the brain such as the striatum and the limbic 
forebrain in rats (Hamilton et al., 1978; Sjörquist et al., 1982), though this is not 
very clear in other studies (Collins et al., 1990). THP and TIQ are formed in very 
trace amounts, and therefore their role in ethanol-stimulated mesolimbic 
dopamine is doubted.
There is an idea that ethanol may increase endogenous morphine (Stefano et al., 
2007; Zhu et al., 2008). It has been determined that endogenous morphine 
synthesis is dependent on dopamine (Boettcher et al., 2005, Zhu et al., 2005; 
Neri et al., 2008). Dopamine combines with 4-phenylacetaldehyde to form a 
precursor of morphine. A summarized simplified version of the proposed 








Figure 2.3. Schematic showing the mechanism of formation of the morphine from dopamine. 
The process involves more steps than shown, but has been simplified. Me = methyl. Figure 
adapted from Herbert et al. (2000).
Does ethanol increase endogenous morphine release in the brain? Haber et al. 
(1997) determined that ethanol induces formation of morphine precursors. 
However, the morphine precursors (THP and S-norcoclaurine) were detected 
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only in the striatum, and only after long term (18 months) intake of ethanol 
(Haber et al., 1997). The morphine precursors were not detected in rats after 6 
months alcohol intake. The idea that acute ethanol may increase endogenous 
morphine is not supported by any evidence. Overall, the idea that ethanol 
increases tetrahydroisoquinolines and endogenous morphine-like alkaloids, such 
that this increase contributes to the mechanism of ethanol-stimulated mesolimbic 
dopamine release is not supported by any evidence.
Ethanol alters the expression of the µ-opioid receptors
There is evidence suggesting that acute ethanol may affect the expression of µ-
opioid receptors. Vukojevic et al. (2008), using the PC12 cellular model, 
proposed that ethanol acts by directly affecting the sorting and re-distribution of 
µ-opioid receptors at the plasma membrane. Also, acute ethanol changes the 
expression of µ-opioid receptors (Méndez et al., 2001). Mendez et al. (2001) 
showed that DAMGO binding was significantly decreased in the VTA and NAcS
30 min and 1 h, respectively, after ethanol administration. It is important to 
mention that the changes in the expression of the µ-opioid receptors could be 
due to changes in the release of opioid peptides. For example, acute DAMGO 
decreases the density of µ-opioid receptors in CHO cell line (Pak et al., 1996), 
therefore acute ethanol may be decreasing µ-opioid receptor density in the VTA 
and NAcS via release of opioid peptides active at the µ-opioid receptors. It is 
therefore important to discuss the interaction between ethanol and the 
endogenous opioid peptides.
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Ethanol stimulates the release of endogenous opioid peptides 
Ethanol affects the synthesis and regulation of β-endorphin (Gianoulakis, 1989). 
Acute and chronic ethanol increases β-endorphin levels in serum and in the brain 
(Schulz et al., 1980; Patel and Pohorecky, 1988, 1989; Anwer and Soliman, 
1995). Acute ethanol increases β-endorphin content in the hypothalamus 
(Gianoulakis et al., 1987; Boyadjieva et al., 1999). Ethanol increases β-endorphin 
content in the NAc and VTA (Rasmussen et al., 1998). The ethanol-induced 
increase in β-endorphin in the studies mentioned above is difficult to interpret as 
it may reflect a product of changes in synthesis, release, transport or metabolism. 
However, microdialysis studies show that ethanol increases β-endorphin levels in 
the NAc (Olive et al., 2001; Marinelli et al., 2003, 2004) and central nucleus of 
the amygdala (Lam et al., 2008) in rats. 
Ethanol affects the synthesis and regulation of enkephalin (Gianoulakis, 1989). 
Ethanol caused an increase in proenkephalin gene in the NAc (Li et al., 1998; de 
Gortari et al., 2000; Méndez and Morales-Mulia, 2006; Oliva et al., 2008). Also, in 
utero ethanol causes an increase in proenkephalin gene in the NAc (Druse et al., 
1999). Additionally, perinatal ethanol alters met-enkephalin in rats (Lugo et al., 
2006). Voluntary ethanol intake (for one month) caused a decrease in 
proenkephalin gene in the NAc (Cowen and Lawrence, 2001). In another study, 
voluntary consumption of ethanol caused an increase in met-enkephalin levels 
within the NAc (Nylander et al., 1994). Acute ethanol increases tissue levels of 
met- enkephalin in the brain (Schulz et al., 1980; Seizinger et al., 1983). 
However, in these tissue level studies, we cannot determine if the met-
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enkephalin was released or synthesized. A better design is the microdialysis 
study undertaken by Marinelli et al. (2005) which shows that ethanol increases 
met-enkephalin levels in the NAc. Ethanol (1.6 g/kg) released met-enkephalin, 
and the time course of met-enkephalin release closely matches up with blood 
ethanol concentration, i.e. met-enkephalin peaked and declined as ethanol 
peaked and declined. Ethanol does not increase met-enkephalin levels in all 
brain structures. For instance, ethanol did not change met-enkephalin levels in 
the central nucleus of the amygdala (Lam et al., 2008). Heavy drinking of ethanol
may decrease plasma met-enkephalin levels (Govoni et al. 1987).
We have discussed the idea that ethanol stimulates the release of endogenous 
opioid peptides. It is important to understand how endogenous opioid peptides 
are released, and to discuss how ethanol may affect this mechanism. Classical 
neurotransmitters (such as glutamate, GABA, acetylcholine) and neuropeptides
(such as opioids) co-exist in many neurons (for review, see Hökfelt et al., 1987a, 
b; Merighi, 2002). The classical neurotransmitters are contained in small synaptic
vesicles (SSVs), whereas the neuropeptides are contained in large dense core 
vesicles (LDCVs). In contrast to SSVs, LDCVs are located at some distance from 
the presynaptic plasma membrane (Ghijsen and Leenders, 2005). Also, the 
release of SSVs takes place at the active synaptic zones, whereas the release of 
LDCV content takes place at remote sites different from the synapse (Karhunen 
et al., 2001; Ghijsen and Leenders, 2005). In general, low frequencies of 
stimulation lead to the release of the classical neurotransmitters. The 
neuropeptide is released only after higher frequencies (or more prolonged bursts 
of low frequencies) of stimulation than is necessary for the exocytotic release of 
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the neurotransmitters (Whim and Lloyd, 1989; Leenders et al., 1999; Ghijsen and 
Leenders, 2005). After depolarization of a neuron, there is a fast release of 
classical neurotransmitter and a slower exocytosis of neuropeptide (Leenders et 
al., 2002; Ghijsen and Leenders, 2005). A summary of the proposed delayed 
effect of opioid peptides is shown in Figure 2.4. 
Figure 2.4. Schematic showing the release of peptides compared to classical 
neurotransmitters. A = small synaptic vesicle containing classical neurotransmitter, B = 
large dense core vesicle containing neuropeptide, C = postsynaptic target, D = distant 
target. The classical neurotransmitter undergoes fast exocytotic release and travels a 
relatively short distance to the postsynaptic target. The peptide undergoes slower 
exocytotic release at sites remote from the synaptic cleft, and therefore has to diffuse 
through some distance before it reaches the postsynaptic target or a distant target. 
Overall, there is a delay in the effect of the neuropeptide.
Apart from depolarization of opioidergic neurons, opioids may also be released 
by the action of other neurotransmitters. Adenosine increases β-endorphin 
release from the hypothalamus (Boyadjieva and Sarkar, 1999). Also, dopamine 
can increase β-endorphin levels in the NAc (Roth-Deri et al., 2003). Acute 
administration of nicotine increases met-enkephalin release in the NAc (Houdi et 
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al., 1991). Serotonin (5HT) increases the extracellular levels of β-endorphin in 
the arcuate nucleus of the hypothalamus and in the NAc (Zangen et al., 1999).
An important question is therefore ‘how does ethanol release the endogenous 
opioid peptides?’ The mechanism of ethanol-stimulated increase of β-endorphin
from the hypothalamus involves many voltage-gated calcium channels (P/Q, N, 
L, and T) (De et al., 1999). Boyadjieva and Sarkar (1999) determined that 
ethanol increases β-endorphin by increasing adenosine, which via adenosine 
receptors, increases β-endorphin. Based on discussions in the previous 
paragraph, it is possible that ethanol also increases endogenous opioids through 
activation of dopaminergic, cholinergic, and serotonergic systems. More research 
needs to be done to establish the mechanism of endogenous opioid peptide 
release via ethanol.
OPIOID MECHANISMS OF ETHANOL-STIMULATED MESOLIMBIC 
DOPAMINE RELEASE
Is there a link between ethanol-stimulated endogenous opioid release and 
ethanol-stimulated mesolimbic dopamine release?
There is a general idea that ethanol stimulates endogenous opioids as part of the 
mechanism of ethanol-evoked mesolimbic dopamine release. For instance, it has 
been suggested that ethanol stimulates β-endorphin release, and this released β-
endorphin acts on µ- (and δ-opioid) receptors in the VTA and/ or NAc to give rise 
to an increase in mesolimbic dopamine (Herz, 1997). However, closer 
examination of the microdialysis data (Olive et al., 2001; Marinelli et al., 2003, 
2004) shows that ethanol-stimulated β-endorphin release in the NAc does not 
65
match up with the typical time course for ethanol-stimulated dopamine release. 
Microdialysis detects an increase in β-endorphin levels only at a time after, and 
not before, dopamine increase in the NAc. There are numerous data showing a 
delay (> 60 min) in β-endorphin release in the NAc (measured via microdialysis) 
after acute ethanol administration (Olive et al., 2001; Marinelli et al., 2003, 2004; 
Lam et al., 2008). From this, we conclude that opioid mediated increase in 
dopamine is probably not due to β-endorphin release and activity in the NAc. In 
fact, evidence seems to suggest that β-endorphin in the NAc is under 
dopaminergic control (Roth-Deri et al., 2003). With regards to ethanol-stimulated 
mesolimbic dopamine release, a probable target for β-endorphin action is the 
VTA. Indeed, preliminary studies show that acute ethanol administration 
increases β-endorphin release in the VTA (Jarjour and Gianoulakis, 2006,
abstract).
From microdialysis data, ethanol stimulated met-enkephalin increase within 30 
min after ethanol administration in the NAcS (Marinelli et al., 2005) and VTA 
(Jarjour and Gianoulakis, 2006, abstract). This increase is detectable at such a 
time that it may correspond to ethanol-stimulated dopamine increases. However 
in these studies, sampling interval was 30 min, making it difficult therefore to 
estimate the nature of the time course of this release. It has been suggested that 
this ethanol-mediated increase in met-enkephalin in the NAc and VTA may 
activate µ- and δ-opioid receptors to give rise to an increase in mesolimbic 
dopamine.
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It is unclear why β-endorphin and enkephalin release is delayed. One possible 
explanation is that when opioids are released, they have to diffuse through some 
distance to act at their targets (Figure 2.4). In summary, there may be a link 
between ethanol-stimulated opioid and dopamine release, but this is not clear,
and more research needs to be done to clarify this.
A closer look at studies investigating the opioid mechanisms of ethanol-
stimulated mesolimbic dopamine release
A look into the literature shows some studies have been done to find an opioid 
mechanism of ethanol-mediated mesolimbic dopamine release. For instance, in 
behavioral studies, naltrexone, a non-selective opioid antagonist, suppresses 
dopamine increase due to ethanol self-administration (Gonzales and Weiss, 
1998). However, naltrexone also suppressed ethanol intake in 6-OHDA-lesioned 
rats (Koistinen et al., 2001), suggesting that dopamine is not required for 
naltrexone suppression of ethanol reinforcement. Similarly, naloxone inhibited 
ethanol intake in rats with 6-OHDA lesions of the mesolimbic pathway 
(Shoemaker et al., 2002). In in situ hybridization studies, chronic ethanol 
consumption increased tyrosine hydroxylase mRNA levels in the VTA, and 
naltrexone (1 mg/kg) treatment suppresses the ethanol-induced increase in the 
VTA tyrosine hydroxylase mRNA levels (Lee et al., 2005).
Benjamin et al. (1993) reported that naltrexone reversed ethanol-induced 
dopamine release in the NAc in awake, freely moving Long Evans rats. However, 
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in this paper (Benjamin et al, 1993), very high ethanol concentration (5%v/v, 
>800 mM) was locally administered (via reverse dialysis) into the NAc throughout 
the experiment (200 min), and the changes in mesolimbic dopamine were 
measured, with naltrexone (systemic) cumulatively (0, 0.25, 0.5, and 1 mg/kg i.p.) 
administered. In this study, the ethanol was continuously infused into the NAc, 
then two 20 min samples were taken, after which saline different doses of 
naltrexone were injected 40 min apart (to allow the collection of two 20 min 
samples after each injection). Details regarding the recovery of the probes, and 
the approximate amount of ethanol reaching the NAc were not given, and thus it 
is impossible to estimate how much ethanol may have reached the NAc. In 
addition to this, when ethanol is administered via reverse dialysis into the NAc, its 
concentration in brain tissue may vary dramatically with distance from the probe 
(Wozniak et al., 1991). This makes conclusions regarding an estimate of the 
amount of ethanol reaching the NAc difficult. Also, when ethanol is administered 
into a specific brain structure like the NAc, as opposed to systemic 
administration, the biological effects have to be carefully interpreted. For 
example, some other studies involving focal application of ethanol into the NAc 
show that the NAc is relatively insensitive to the dopamine stimulating effects of 
ethanol, except when very high concentrations of ethanol are used (Wozniak et 
al., 1991; Yim et al., 1998; Tuomainen et al., 2003).
68
Following systemic administration, the concentration of ethanol reaching the 
brain peaks and then decreases as the ethanol is metabolized and undergoes 
clearance. In this study, continuous intra-NAc administration of ethanol was 
given, introducing a question as to whether the measured dopamine response 
can ever be attained physiologically. For example, in other studies utilizing 
reverse dialysis of ethanol into the NAc, the ethanol-evoked dopamine response 
is not continuous throughout the administration of ethanol (Tuomainen et al., 
2003; Lof et al., 2007). In the study by Lof et al. (2007), they showed that the 
NAc dopamine increases due to focally administered ethanol last only about 40 
min, regardless of continuous intra-NAc ethanol infusion. Another example can 
be seen from the work by Tuomainen et al. (2003) in which they found that a 
reverse dialysis of 800 mM of ethanol continuously for 1 h into the NAc of rats 
increased dopamine, but the dopamine peaked at 15 min and was back to 
baseline at around 45 min, even while the ethanol was still continuously 
administered. Going back to the paper by Benjamin et al. (1993), it is likely, 
therefore, that at time > 40 min after the start of intra-NAc ethanol infusion (and 
before the injection of the naltrexone doses) there may be a time-dependent 
decrease in dopamine release (see Tuomainen et al., 2003; Lof et al., 2007). 
This implies that, absent any appropriate controls, the observed changes in 
dopamine may be due to a time-related decrease in ethanol-induced dopamine 
release and not due to naltrexone administration. An appropriate control would 
have been to repeat the same experiment, substituting saline for all 
corresponding cumulative naltrexone injection doses, in order to identify if there 
is a time-dependent change in ethanol-induced dopamine throughout the 
duration of the experiment (200 min) independent of naltrexone administration.
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Also in this experiment, rats were injected i.p. 4 times with saline or various 
naltrexone doses. This procedure is stressful, and it is thought that stress can 
affect endogenous opioid levels (Patel and Pohorecky, 1988; Marinelli et al., 
2004). Furthermore, there may be an involvement of endogenous opioid 
mechanisms in the interaction between stress and ethanol (Trudeau et al., 1991).
We, therefore, cannot exclude stress as a confounding variable in the results 
obtained in the experiment. An adequate control to address this has been 
mentioned above, or alternatively a less stressful route of administration can be 
used. A typical dopamine response includes an initial increase, and then a 
decrease back to baseline. In this experiment, the initial increase in dopamine 
was supposedly sustained throughout the experiment, and decreased by the 
cumulative doses of naltrexone. With all the limitations mentioned above, we 
cannot conclude with confidence, that naltrexone attenuates ethanol-evoked 
dopamine release in the NAc, and a better experimental design needs to be 
done.
Inoue (2000) examined the effect of naltrexone (systemic) on the ethanol 
(systemic) evoked increases in the firing rates of VTA dopaminergic neurons in 
anesthetized male Sprague Dawley rats. The conclusion of this research work 
(Inoue, 2000) is that naltrexone attenuates ethanol-evoked increases in VTA 
dopaminergic neuron firing, but only at very high naltrexone doses (30 mg/kg). In 
any case, 3.0 mg/kg of naltrexone, which is a pharmacologically relevant dose, 
had no effect on ethanol induced VTA dopamine neuron firing activity. This data 
can be interpreted to mean that, notwithstanding the administration of 3.0 mg/kg 
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naltrexone, ethanol still increased the firing of VTA dopamine neurons. One 
limitation is that VTA dopamine neuron firing does not necessarily correspond to 
a release of dopamine in the NAc. Also, even though this research data 
concluded that naltrexone resulted in depression of VTA dopaminergic neuronal 
firing rates activated by acute ethanol administration in the NAc, the doses of 
naltrexone (30 mg/kg) which achieved this were extremely high and may have 
achieved this through non-opioid mechanisms. 
In separate experiments in this study (Inoue, 2000), the accumulation of L-DOPA 
(which is considered as an indicator of dopamine metabolism or release) in the 
NAc after ethanol administration was measured. Ethanol 2.5 g/kg (i.p.) caused 
approximately 40% increase in L-DOPA in the NAc. Naltrexone 3.0 and 10.0 
mg/kg were ineffective in suppressing the accumulation of L-DOPA in the NAc 
due to 2.5 g/kg ethanol. A major limitation of this work is that rats were 
decapitated, and the NAc was extracted for L-DOPA analysis, 90 min after 
ethanol administration. However, in other microdialysis studies, ethanol (2.5 g/kg, 
i.p.) increases dopamine in the NAc shortly after administration, and the 
dopamine levels are back to baseline at 60 min after ethanol administration 
(Blomqvist et al., 1993, 1997; Olausson et al., 1998). L-DOPA accumulation in 
the NAc was therefore analyzed after dopamine levels in the NAc would have 
come back to baseline. We therefore cannot correlate the L-DOPA levels with 
ethanol-mediated dopamine release. The Inoue (2000) study showed that 
naltrexone (30 mg/kg), but not naltrexone (3 and 10 mg/kg), was effective in 
suppressing ethanol-mediated increase in VTA dopamine neuron firing and 
ethanol-mediated accumulation of L-DOPA in the NAc. With the limitations of this 
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study, it is not clear if naltrexone suppresses acute ethanol-mediated increase in 
mesolimbic dopamine release 
It is also not clear if the µ-opioid receptors play a role in the mechanism of 
ethanol-stimulated dopamine release. Ethanol-stimulated mesolimbic dopamine 
release is attenuated in some, but not all, models of the µ-opioid receptor 
knockout mice (Job et al., 2007). A major limitation with the knockout studies is 
that lifelong deletion of a gene can lead to compensatory mechanisms and 
therefore data obtained from knockout models should be interpreted very 
carefully, preferably with some pharmacological antagonism studies supporting 
the findings. Naloxonazine (15 mg/kg i.p.), an irreversible selective µ1-opioid 
antagonist, suppresses ethanol-induced mesolimbic dopamine release (Tanda 
and Di Chiara, 1998) in freely-moving animals, suggesting that the µ1-opioid 
receptor is involved in this mechanism. However, a limitation of naloxonazine is 
that it is thought to block δ-opioid receptors (Dray and Nunan, 1984), and since 
δ-opioid receptors may be involved in ethanol-induced dopamine release in the 
NAc (Acquas et al., 1993), it may be argued that the effect may be due to µ1- or 
δ-opioid receptors or both. However, naloxonazine has a 200 fold higher 
selectivity of µ1- over δ-opioid receptors (Raynor et al., 1994). Honkanen et al. 
(1996) showed that doses of naltrindole which block δ-opioid function had no 
effect on ethanol intake whereas naloxonazine (15 mg/kg i.p.) did, suggesting 
that the effects of naloxonazine at this dose are predominantly due to µ1-opioid 
receptors. We believe that naloxonazine is acting predominantly at the µ1- opioid 
receptor (see discussion on naloxonazine in section on the pharmacology of the 
µ-opioid antagonists). Therefore, the idea that naloxonazine is acting through the 
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δ-opioid is not very strong, making a case for a role of µ-opioid receptors in 
ethanol-evoked dopamine release in the NAc (Tanda and Di Chiara, 1998). 
However, naloxonazine is not effective in suppressing ethanol-stimulated 
mesolimbic dopamine in all studies (see Job et al., 2007). In summary, it is not 
clear that µ-opioid inhibition leads to an attenuation of ethanol-stimulated 
mesolimbic dopamine release (Tanda and Di Chiara, 1998; Job et al., 2007).
Proposed mechanism of µ-opioid-mediated ethanol-stimulated mesolimbic 
dopamine release
Ethanol increases endogenous opioids 
(Olive et al., 2001; Marinelli et al., 2003, 
2004, 2005, 2006). Endogenous 
opioids, such as enkephalin (Daugé et 
al., 1992; Cador et al., 1989; Kalivas 
and Richardson-Carlson, 1986), β-
endorphin (Iyenger et al., 1989; 
Spanagel et al., 1990a, 1991a, b), 
endomorphin (Huang et al., 2004; 
Okutsu et al., 2006; Terashvili et al., 
2008) all increase dopamine release in 
the NAc. It is hypothesized that ethanol 
increases dopamine, in part, by 
stimulating endogenous opioid peptides which in turn act at µ-opioid receptors to 
increase dopamine in the NAc (Figure. 2.5). Based on the scheme in Figure.2.5, 
Figure 2.5. Schematic showing proposed 
µ-opioid mechanism of ethanol-stimulated 
mesolimbic dopamine release.
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therefore, blockade of the µ-opioid receptors should lead to a suppression of 
ethanol-stimulated mesolimbic dopamine release.
SUMMARY AND SPECIFIC AIMS
We discussed data showing that ethanol increases dopamine release in the NAc. 
Also, ethanol stimulates the release of endogenous opioid peptides. It is 
proposed that ethanol increases mesolimbic dopamine, in part, by stimulating the 
release of endogenous opioids to activate the µ-opioid receptor, leading to a 
disinhibition of VTA dopaminergic neurons to result in an increase in dopamine in 
the NAc. We ended the review, by discussing experiments that had been done 
previously to determine the role of the µ-opioid receptor in the mechanism of 
ethanol-induced mesolimbic dopamine release. Previous experiments concluded 
that the µ-opioid receptors play a role in ethanol-evoked mesolimbic dopamine 
release. After a careful look into the literature regarding previous experimental 
designs and limitations, we are convinced that the conclusions need to be 
interpreted with care, and we are convinced that more comprehensive research 
needs to be done to effectively characterize the role of the µ-opioid receptor in 
the mechanism of ethanol-evoked dopamine release in the NAcS, and we 
propose such an experiment.
For the purposes of this project, we will study the involvement of the µ-opioid 
receptor in ethanol-induced dopamine release in the NAcS in male rats. In our 
experiments, Long Evans rats will be used, and dialysate dopamine and ethanol 
will be obtained using in vivo microdialysis, and analyzed using HPLC and GC, 
respectively. Our hypothesis is that the µ-opioid receptor plays a role in ethanol-
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stimulated dopamine release in rats; therefore blockade of the µ-opioid receptor 
should decrease this effect. This hypothesis will be tested by the following 
specific aims:
(1) To find out if naltrexone affects basal dopamine levels in the NAcS. This will 
be done by administering cumulative intravenous (i.v.) doses of saline and 
different doses of naltrexone to determine if there is a change in dopamine in the 
NAcS.
(2) To experimentally find an effective dose of naltrexone to suppress morphine-
evoked dopamine release in the NAcS. We will look for a dose-dependent effect 
of systemic naltrexone on morphine-stimulated dopamine release in the NAcS. 
This will be done by i.v. pretreatment of rats with vehicle or different doses of
naltrexone and subsequently measuring morphine-stimulated dopamine release 
in the NAcS. 
(3) To measure the effect of systemic naltrexone on ethanol-stimulated dopamine 
release in the NAcS. This will be done by i.v. administration of vehicle, or a dose 
of naltrexone that is effective in abolishing morphine-evoked NAcS dopamine 
release, and determining the effect of these effective doses on ethanol-
stimulated dopamine release.
(4) To measure the effect of a specific µ-opioid antagonist on morphine-
stimulated dopamine release. This will be done by subcutaneous (s.c.) 
pretreatment of rats with vehicle or β-funaltrexamine, and subsequently 
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measuring dopamine release in the NAcS due to i.v. morphine administered 20-
24 hours later.
(5) To measure the effect of a specific µ-opioid antagonist on ethanol-stimulated 
dopamine release in the NAcS of Long Evans rats. This will be done by s.c. 
pretreatment of rats with vehicle or the dose of β-funaltrexamine that attenuated 
morphine-evoked dopamine release in the NAcS (in previous experiment), and 
subsequently measuring dopamine release in the NAcS due to i.v. ethanol
administered 20-25 h later.
76
Chapter 3. The role of the µ-opioid receptors in the 
mechanism of ethanol-stimulated dopamine release in 
the nucleus accumbens shell in ethanol-naïve rats
Abstract
Background: It has been proposed that the µ-opioid receptor plays a role in 
ethanol-reinforcement through modulation of the mechanism of ethanol-
stimulated mesolimbic dopamine release. Our hypothesis is that blockade of the 
µ-opioid receptors attenuate ethanol-mediated increases in dopamine release in 
the nucleus accumbens shell.
Methods: Ethanol-naïve male Long Evans rats (n = 95) were prepared for in vivo
microdialysis and intravenous drug infusion. Experiments were done to 
determine the effect of naltrexone and β-funaltrexamine on morphine- and 
ethanol-stimulated dopamine release in the nucleus accumbens shell.
Results: Naltrexone and β-funaltrexamine, via blockade of the µ-opioid 
receptors, suppressed the prolongation, but not the initiation of the dopamine 
release by ethanol.
Conclusions: The µ-opioid receptors are involved in a delayed component of 
ethanol-stimulated dopamine release in the nucleus accumbens shell in ethanol-
naïve rats.




The mesolimbic dopaminergic system, which includes the pathway from the 
ventral tegmental area (VTA) to the nucleus accumbens (NAc), is thought to play 
a role in ethanol reinforcement (for review, see Gonzales et al., 2004). 
Endogenous opioidergic systems are also thought to play a role in ethanol 
reinforcement (for review, see Herz, 1997). Naltrexone, a non-selective opioid 
antagonist, is FDA approved for clinical use in the management of alcoholism 
(Volpicelli et al., 1992, 1995; O’Brien et al., 1996). Also, β-funaltrexamine, a 
selective µ-opioid antagonist, is effective in suppressing ethanol intake in rats 
(Krishnan-Sarin et al., 1998; Stromberg et al., 1998a), and there is a strong 
suggestion that the µ-opioid receptors play a major role in ethanol intake and 
reinforcement (Myers & Robinson, 1999; Roberts et al., 2000; Hall et al., 2001; 
Hyytia and Kiianmaa, 2001; Becker et al., 2002; Lasek et al., 2007). It has been 
proposed that blockade of the µ-opioid receptors leads to the suppression of
ethanol reinforcement partly by attenuating ethanol-stimulated mesolimbic 
dopamine activity (Herz, 1997).
Naltrexone, in an operant self-administration study, attenuated the NAc 
dopamine increase that occurs as a result of ethanol self-administration 
(Gonzales and Weiss, 1998) in ethanol-experienced rats. However, in another 
behavioral study in ethanol-experienced rats, naltrexone suppression of ethanol 
intake was retained in ethanol-experienced rats with lesions of the mesolimbic 
dopamine pathway (Koistinen et al., 2001) suggesting that the mechanism 
involved in naltrexone suppression of ethanol reinforcement may not even 
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require mesolimbic dopamine. It is also not very clear if naltrexone attenuates 
acute ethanol-mediated increases in mesolimbic dopamine activity in ethanol-
naïve rats. For instance, even though Benjamin et al. (1993) reported that, in 
ethanol naïve rats, naltrexone attenuated ethanol-induced dopamine release in 
the NAc, Inoue (2000) reported that naltrexone, at pharmacologically relevant 
doses, did not decrease acute ethanol-induced increase in the firing rates of VTA 
dopaminergic neurons in anesthetized ethanol-naïve rats. More research needs 
to be done to clarify the effect of naltrexone on ethanol-stimulated mesolimbic 
dopamine release. Naltrexone is non-selective, blocking µ-, δ- and κ-opioid 
receptors. The opioid receptors are involved in the modulation of mesolimbic 
dopamine (Herz, 1997). Therefore, it is important to characterize the respective 
contribution of the individual receptor types to the effect of naltrexone on ethanol-
stimulated dopamine release.
A literature search shows that some experiments to characterize the contribution 
of the µ-opioid receptor to the mechanism of ethanol-stimulated mesolimbic 
dopamine release have been done. For instance, Tanda and Di Chiara (1998) 
reported that naloxonazine, an irreversible selective µ1-opioid receptor subtype 
antagonist, suppressed ethanol-induced mesolimbic dopamine release. 
However, naloxonazine did not block ethanol-stimulated mesolimbic dopamine 
release in all animal models (Job et al., 2007). Furthermore, naloxonazine is 
thought to also block δ-opioid receptors (Dray and Nunan, 1984), and there is 
evidence that δ-opioid receptors play a role in the mechanism of ethanol-
stimulated mesolimbic dopamine release (Acquas et al., 1993). The role of the µ-
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opioid receptor in the mechanism of ethanol-evoked mesolimbic dopamine 
release is not clear, and more work needs to be done to clarify this.
In vivo microdialysis shows that intravenous (i.v.) ethanol increases dopamine in 
the nucleus accumbens shell (NAcS) in awake, freely moving naïve Long Evans 
rats (Howard et al., 2008). In the present study, our goal was to test the 
hypothesis that in naïve rats, blockade of the µ-opioid receptors inhibits ethanol-
mediated increases in dopamine release in the NAcS. To test this hypothesis, we 
prepared male Long Evans rats for i.v. drug administration and intracerebral 
microdialysis from the NAcS and examined the effect of naltrexone (i.v.) and β-
funaltrexamine (s.c.) pretreatments on morphine (positive control experiments) 
and ethanol-evoked increases in dopamine release. 
Materials and Methods
Animals
Male Long-Evans rats (n = 95) (Charles River Laboratories, Wilmington, MA), 
weighing 280-407 g on dialysis day, were used for these experiments. Sixty-nine 
and twenty-six rats were used for the naltrexone and β-funaltrexamine 
experiments, respectively. The rats were housed individually in a temperature 
(25˚C) and light (12 h light/12 h dark) controlled room, and had access to food 
and water ad libitum. The rats were handled for at least four days prior to 
surgery. All procedures were carried out in compliance with the guidelines set 
forth by the National Institutes of Health Guide for the Care and Use of 
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Laboratory Animals and the Institutional Animal Care and Use Committee of the 
University of Texas at Austin.
Surgery
A jugular catheter was inserted, and a guide cannula was placed over the NAc in 
each rat using the procedure of Howard et al. (2008). The catheter was placed in 
the jugular vein, passed subcutaneously to exit an incision on the head. 
Intravenous catheters were constructed from silastic tubing (0.30 mm ID, 0.64 
mm OD, 0.15 mm wall thickness, Fisher Scientific, Hampton, NH), a cannula (22 
gauge, Plastics One, Roanoke, VA), and silicon adhesive (DAP Inc., Baltimore, 
MD). The rats were under isoflurane anesthesia (2.0%) during stereotaxic and 
jugular catheterization surgery. The guide cannula used for microdialysis (21 
gauge, Plastics One, Roanoke, VA) was implanted above the shell (coordinates 
in mm relative to Bregma: AP +2.2, ML +0.9, DV -3.8) of the NAc while the 
animal was in a stereotaxic frame. The DV coordinate represents the bottom of 
the guide cannula, and the probe extends an additional 4.0 mm below the 
cannula when seated into the guide. An obturator was placed in the guide 
cannula to prevent blockage. Rats were allowed to recover from surgery for 3-6 
days before experiments. 
Microdialysis
The evening before the dialysis experiment, a laboratory constructed probe (1.5 
mm active membrane length, 270 µm OD, 18,000 molecular weight cut-off) was 
implanted through the guide cannula and perfused (CMA 100 microinjection 
pump, Acton, MA) with artificial cerebrospinal fluid (ACSF: 149 mM NaCl, 2.8 mM 
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KCl, 1.2 mM MgCl2, 1.2 mM CaCl2, 0.25 mM ascorbic acid, 5.4 mM D-glucose).  
The rats were placed in individual chambers with free access to water and food, 
and the flow rate was lowered to 0.2 µL/min, and allowed to run overnight. The 
next morning, the flow rate was increased to 2.0 µL/min., and allowed to run at 
this flow rate for two hours before the dialysis experiment began. Samples were 
collected at 5-min intervals. In one experiment, naltrexone was cumulatively 
administered i.v. to determine the effect of naltrexone on basal dopamine levels. 
In another experimental design, naltrexone was administered i.v. 20 min before 
i.v. drug (morphine, ethanol and saline) treatment. In these experiments, 
morphine (1 mg/kg) was delivered as a bolus dose, ethanol (1g/kg) and 
equivalent volume saline treatments were delivered at the rate of 4 mL/min. In 
yet another experimental design, β-funaltrexamine was administered s.c. 20-25 h 
before rats were given i.v. drug treatments (morphine, ethanol and saline). In 
these experiments, all animals received saline, followed by either morphine or 
ethanol. Upon completion of the experiments, the perfusate was switched to 
calcium-free ACSF. A 5-min sample was taken after 1 h to verify that dopamine 
recovered in the experimental samples was due to calcium-dependent exocytotic 
release. For all groups, every dialysis sample was analyzed for dopamine, and 
ethanol was determined in the post-infusion samples in the ethanol experiments.
Histology
After the dialysis experiment (1-3 days), the rats were overdosed with sodium 
pentobarbital (150 mg/kg, i.v.). The rats were perfused intracardially with saline 
followed by 10% formalin, and the brains were extracted and placed in 10% 
formalin overnight. The brains were sectioned (100 µm thick) with a Vibratome 
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(Leica, Nussloch, Germany) and then stained with cresyl violet to confirm probe 
placement in the NAcS. The probe tracks were mapped using the atlas of 
Paxinos and Watson (1986), and Paxinos et al. (1999).
High Pressure Liquid Chromatography (HPLC) and Gas Chromatography (GC)
Dialysate dopamine was analyzed using HPLC with electrochemical detection. 
The system used a Polaris 3µ C18 column (50 x 2 mm, Varian, Lake Forest, CA). 
The mobile phase (pH = 5.6) consisted of 0.50 g octanesulfonic acid, 0.05 g 
decanesulfonic acid, 0.13 g ethylenediaminetetraacetic acid, 11.1 g NaH2PO4, 
and 150 ml methanol, all in 1 L of deionized water. Dialysate samples were 
mixed with ascorbate oxidase at 4˚C prior to injection. Dopamine was detected 
with an electrochemical detector (Model VT03, Antec Leyden, Netherlands) at a 
potential of + 345 mV (relative to an Ag/AgCl reference). A second system was 
used for some samples in which the reference was an in situ Ag/AgCl (ISAAC). 
KCl was added to the mobile phase in appropriate concentrations in this case 
(4.47 g/L). The limit of detection was ~0.2 nM. The peaks were recorded using 
EZChrom software, and the concentration of dopamine in each sample was 
determined using external standards.
Ethanol was analyzed in 2 µl aliquots that were transferred from the dialysate 
sample into 2 ml gas chromatography vials immediately after sample collection. 
Dialysate ethanol concentrations were determined following the method of 
Howard et al. (2008). A Varian CP 3800 gas chromatograph with flame ionization 
detection and a Varian 8200 headspace autosampler was used to analyze the 
concentrations of ethanol in the samples. The stationary phase was an HP 
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Innowax capillary column (30 m x 0.53 mm x 1.0 µm film thickness) and helium 
was the mobile phase. Resulting ethanol peaks were recorded using Varian Star 
Chromatography Workstation software, and calibration was achieved using 
external standards.
Drugs and drug treatments
Morphine sulphate salt pentahydrate (NIDA Drug Supply Program) was dissolved 
in saline (1 mg/mL). Naltrexone hydrochloride (Sigma-Aldrich, St. Louis, MO) 
was dissolved in saline. β-funaltrexamine hydrochloride (Tocris Bioscience, 
Ellisville, MO) was dissolved in de-ionized water and appropriate NaCl was 
added to the resultant solution to make it 0.9%w/v (normal saline). A 10% w/v 
solution of ethanol in saline was made from ethanol (95%) (Aaper Alcohol and 
Chemical Co., Shelbyville, KY). All drugs were administered via the i.v. route 
except β-funaltrexamine which was administered via the s.c. route.
Data Analysis
The dopamine data was either used directly (naltrexone cumulative experiment) 
or transformed to percent of basal values (all other experiments). The Area 
Under the Curve (AUC), which is the difference between post-infusion dopamine 
levels and baseline, was calculated for dopamine data for some experiments. 
The analysis of the dopamine time course was done using repeated measures 
ANOVA using SPSS (SPSS Inc, Chicago, IL). The analysis of the AUC was done 
using One-way ANOVA using SPSS. The criterion for type I error was set to P < 
0.05. We performed post hoc contrasts (Bonferroni corrected), comparing 
individual time points between treatment groups, and individual time points with 
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basals within groups when significance was detected for time, or drug treatment 
x time interaction. Values are reported as mean + SEM.
For all experiments, the within subject variable was time. For the experiment 
involving naltrexone and morphine, the between subject variable was naltrexone 
dose (4 levels). For the naltrexone and ethanol experiment, we have one 
between subject factor (naltrexone dose, with 3 levels). For experiments 
involving β-funaltrexamine, the between subject variable was β-funaltrexamine (2 
levels). For all experiments, there were 20 missing data points (out of a total of 
1510) due to problems with chromatography or sample collection. The missing 
points were estimated by taking the average of the values on either side of the 
missing point and the degrees of freedom in the final statistical analyses were 
corrected for the estimated data.
Results
Histology and calcium dependency of dialysate dopamine
The microdialysis probe placements in the NAcS are shown in Figure 3.1. Rats 
that had probes (a) completely in the NAcS (89% of rats) and (b) predominantly 
in the NAcS with not more than 35% of the probe in the border between the NAc 
shell and the core (11% of rats) were included in the analysis.
The Ca2+ dependency of dialysate dopamine was ascertained for all rats used in 
this study. The criterion for acceptable Ca2+ dependency was the attainment of at 
least 60% reduction in extracellular dopamine during Ca2+ free ACSF perfusion 
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compared with regular ACSF perfusion. For all experiments, the mean reduction 
for extracellular dopamine was 85 ± 2%.
Naltrexone does not alter basal levels of dopamine. 
We did three naltrexone experiments. One experiment involved cumulative i.v.
administration of saline and different doses of naltrexone (0.125, 0.25, 0.5 
mg/kg). Another experiment involved i.v. infusion of saline or different doses of 
naltrexone (0.01, 0.1, and 0.3 mg/kg) 20 min before infusion of a single dose of 
morphine. Yet another experiment involved i.v. infusion of saline or different 
doses of naltrexone (0.3 and 1.0 mg/kg) 20 min before infusion of ethanol or 
Figure 3.1. Histological analysis to confirm probe placements in the nucleus accumbens 
shell. Coordinates are from Bregma.
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saline. For all experiments, saline infusions (controls) did not cause any change 
in basal dopamine levels. In the naltrexone cumulative dosing experiment, 
naltrexone did not cause any change in dopamine basal levels (F 19, 94 = 1.06, P 
> 0.05, time) (Figure 3.2).
Figure 3.2. Naltrexone does not change basal levels of dopamine. This shows the 
dopamine response in the shell of the nucleus accumbens of male Long Evans rats after 
i.v. pretreatment with cumulative doses of naltrexone (n = 6). Each rat received saline
and naltrexone doses (0.125, 0.25, and 0.5 mg/kg), with infusions administered 20 min 
apart. The arrows indicate the point of infusion.
In the naltrexone and morphine experiment, naltrexone (0.01, 0.1 and 0.3 mg/kg) 
did not alter basal dopamine levels. ANOVA showed no significant difference in 
dopamine levels after infusion of saline (n = 6) or naltrexone doses (mg/kg): 0.01 
(n = 5), 0.1 (n = 6), and 0.3 (n = 7) (F 15, 99 = 0.69, P > 0.05, for the naltrexone 
dose X time interaction). Before naltrexone pretreatment, basal dopamine levels 
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(nM) were 1.0 ± 0.3, 1.9 ± 0.4, 1.8 ± 0.5, and 1.2 ± 0.4 for saline and naltrexone 
doses 0.01, 0.1, and 0.3 mg/kg respectively. In the naltrexone and ethanol 
experiment, naltrexone (0.3 and 1.0 mg/kg) did not alter basal dopamine levels. 
ANOVA showed no significant change in dopamine levels after saline (n = 12), 
naltrexone 0.3 mg/kg (n = 14), or 1.0 mg/kg (n = 13) infusions (F 14, 248 = 1.25, P 
> 0.05, for the naltrexone dose X time interaction). For these experiments basal 
dopamine levels (nM) (before naltrexone infusion) were 1.0 ± 0.2, 1.2 ± 0.2, and 
1.2 ± 0.2 respectively.
Naltrexone inhibited morphine-evoked mesolimbic dopamine release.
We infused rats with saline or different doses of naltrexone (0.01, 0.1, 0.3 mg/kg, 
i.v.) before infusion of morphine (1 mg/kg, i.v.). For rats pretreated with saline, 
morphine increased dopamine (about 50% above baseline), and this increase 
was sustained throughout the time course analyzed (Figure 3.3). Naltrexone 
dose-dependently attenuated morphine-stimulated dopamine release in the 
NAcS. We found that, compared to saline, naltrexone caused a significant 
reduction in morphine-stimulated dialysate dopamine (F 21, 138 = 9.50, P < 0.05, 
for the naltrexone dose x time interaction). Post hoc analyses revealed that at 5 
min after morphine infusion, saline controls were different from all naltrexone
pretreated rats. At all other time points afterwards, saline controls were different 
from naltrexone doses 0.1 and 0.3 mg/kg (P < 0.05) (Figure 3.3). Also, a 
difference between the effect of different doses of naltrexone on the AUC of 
morphine-evoked dopamine was detected (F 3, 23 = 55.87, P < 0.05), and further 
analysis using Tukey HSD showed that naltrexone doses (mg/kg) 0.1 and 0.3, 
but not 0.01, are different from controls (Figure 3.4). Basal dopamine levels (nM) 
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(before morphine infusion) for saline and naltrexone doses 0.01, 0.1, and 0.3 
mg/kg were 1.0 ± 0.3, 1.9 ± 0.4, 1.8 ± 0.5 and 1.2 ± 0.4 respectively (n = 5-7). 
Figure 3.3. Naltrexone dose-dependently inhibits morphine-evoked dopamine release in 
the nucleus accumbens shell (time course). This shows the dopamine response in the 
shell of the nucleus accumbens of male Long Evans rats after i.v. pretreatment with 
saline (control) and naltrexone (0.01, 0.1, 0.3 mg/kg) and i.v. infusion with morphine (1 
mg/kg). Each rat received an i.v. pretreatment of the different naltrexone doses followed 
20 min later by morphine (1 mg/kg) (n = 5 - 7). Mean + SEM are shown for each point. * 
shows a significant difference from basals of all doses. Arrow indicates the morphine 
infusion time.
89
Figure 3.4. Naltrexone dose-dependently inhibits morphine-evoked dopamine release in 
the nucleus accumbens shell (AUC). This shows the AUC (% basal dopamine) in the 
nucleus accumbens shell after i.v. pretreatment with saline and naltrexone doses (0.01, 
0.1, and 0.3 mg/kg) followed by i.v. infusion with morphine (1 mg/kg). * shows a 
significant difference from saline controls.
Naltrexone attenuated ethanol-evoked mesolimbic dopamine release. 
For these experiments, we infused saline or naltrexone (0.3 or 1.0 mg/kg) 20 min 
before ethanol (10%w/v, 1 g/kg, i.v.) or saline (equivalent volume to ethanol) to 
determine the effect of naltrexone on ethanol-evoked dopamine release. For 
controls, ethanol increased dopamine (~33% from baseline), and this increase 
was sustained for at least 20 min (Figure 3.5), while saline did not cause an 
90
increase in dopamine. ANOVA showed a naltrexone dose X time interaction (F 18, 
292 = 1.67, P < 0.05).
For naltrexone pretreated rats, ethanol also increased dopamine (~24%), but this 
increase was not sustained beyond the first 5 min (Figures 3.6 and 3.7). ANOVA 
also revealed an ethanol X time interaction (F 9, 292 = 10.95, P < 0.05), detecting 
that in all rats ethanol, but not saline, caused an increase in dopamine (Figure 
3.8, saline data not shown). Post hoc analysis showed that compared to controls, 
Figure 3.5. Ethanol, but not saline, increases dopamine in the nucleus accumbens shell. 
This shows dopamine response in the shell of the nucleus accumbens after i.v. 
pretreatment with saline and i.v. infusion with ethanol or saline. Each rat received an i.v. 
pretreatment of saline followed 20 min later by ethanol (1 g/kg, 10% w/v) (n = 8) or saline 
(n = 4) at the time indicated by the arrow. Mean + SEM are shown for each point. *
indicates significant difference from baseline. Volumes are 1 mL/ kg and 10 mL/ kg for 
naltrexone and ethanol/saline respectively. Arrow indicates the saline/ethanol infusion 
time.
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naltrexone prevents a prolongation of the increase in dopamine following ethanol 
administration (Figure 3.8). Naltrexone doses- 0.3 and 1.0 mg/kg do not dose-
dependently attenuate ethanol-stimulated dopamine release. Though different 
from controls, ANOVA reveals that, with regards to the effect on ethanol-
stimulated dopamine release, naltrexone 0.3 and 1.0 mg/kg are not different from 
each other (Figure 3.8).
Figure 3.6. Naltrexone (0.3 mg/kg) attenuates the prolongation of ethanol-stimulated 
dopamine response. This shows dopamine response in the shell of the nucleus 
accumbens of male Long Evans rats after i.v. pretreatment with naltrexone (0.3 mg/kg) 
and i.v. infusion with ethanol or saline. Each rat received an i.v. pretreatment of 
naltrexone (0.3 mg/ kg) followed 20 min later by ethanol (1 g/kg, 10% w/v) (n = 8) or 
saline (n = 6). * indicates significant difference from baseline. Volumes are 1 mL/ kg and 
10 mL/ kg for naltrexone and ethanol/saline respectively. Arrow indicates the 
saline/ethanol infusion time.
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Figure 3.7. Naltrexone (1.0 mg/kg) attenuates the prolongation of ethanol-stimulated 
dopamine response. This shows dopamine response in the shell of the nucleus 
accumbens of male Long Evans rats after i.v. pretreatment with naltrexone (1.0 mg/kg) 
and i.v. infusion with ethanol or saline. Each rat received an i.v. pretreatment of 
naltrexone (1.0 mg/ kg) followed 20 min later by ethanol (1 g/kg, 10% w/v) (n = 8) or 
saline (n = 5). * indicates significant difference from baseline. Volumes are 1 mL/ kg and 
10 mL/ kg for naltrexone and ethanol/saline respectively. Arrow indicates the 
saline/ethanol infusion time.
93
Figure 3.8. Naltrexone attenuates a delayed component of ethanol-stimulated dopamine 
response. This shows dopamine response after i.v. pretreatment with saline, naltrexone 
0.3 and 1.0 mg/kg and i.v. infusion with ethanol (1 g/kg, 10% w/v). The data for control 
and each naltrexone dose is collapsed across all ethanol and saline infusions. Saline 
infusion does not change dialysate dopamine levels, and is therefore not shown. The 
analysis was restricted to first 20 min after infusion. The # and the + show significant 
difference between pretreatment with saline and naltrexone 0.3 mg/kg,and between 
saline and naltrexone 1.0 mg/kg, respectively.
It is important to add that ANOVA revealed that there was no effect of saline 
infusion on the control and naltrexone pretreated rats within the first 20 min after 
saline infusion, but afterwards there was a gradual decrease in basal dopamine 
(see Figures 3.5, 3.6, 3.7). Therefore, the analysis was restricted to the first 20 
min after ethanol or saline infusion as shown in Figure 3.8. Basal dopamine 
concentrations (nM), before ethanol or saline infusions, for rats pretreated with 
saline and administered ethanol and saline were 1.0 ± 0.3 and 1.1 ± 0.3, 
respectively. For rats pretreated with naltrexone dose 0.3 mg/kg and infused with 
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saline or ethanol, the basal dopamine levels (nM) were 0.9 ± 0.2 and 1.2 ± 0.1,
respectively. For naltrexone 1.0 mg/kg pretreated rats, the basal levels (nM) were 
1.2 ± 0.4 and 1.3 ± 0.1 for saline and ethanol, respectively.
Naltrexone did not alter peak ethanol concentration and time course. The peak 
ethanol concentrations were 5.9 ± 0.4, 6.5 ± 0.5 and 6.3 ± 0.6 mM for control, 
naltrexone 0.3 and 1.0 mg/kg (n = 8 each) pretreated rats, respectively. There
was no significant difference in the peak ethanol concentration (F 2, 23 = 0.40, P > 
0.05, for the naltrexone dose x time interaction) and in the time course of ethanol 
(F 11, 231 = 0.62, P > 0.05, for the naltrexone dose x time interaction) (Figure 3.9).
95
Figure 3.9. Naltrexone does not affect the peak and time course of ethanol in the 
nucleus accumbens shell. This shows ethanol concentrations in the shell of the nucleus 
accumbens of rats after i.v. pretreatment with saline and naltrexone (0.3 and 1 mg/kg) 
and i.v. infusion with ethanol (1 g/kg, 10% w/v). Mean + SEM are shown for each point. 
All groups have n = 8. Arrow indicates the ethanol infusion time.
β-funaltrexamine inhibited morphine-evoked mesolimbic dopamine release.
In these experiments, we injected saline or β-funaltrexamine (20 mg/kg, s.c.) 
followed 20-24 h later by saline and morphine (1 mg/kg, i.v.) to determine the 
effect of β-funaltrexamine on morphine-induced dopamine release in the NAcS. 
Morphine (but not saline) increased the release of dopamine in the NAcS 
(Figures 3.10 and 3.11).
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Figure 3.10. Saline does not increase dopamine in control and β-funaltrexamine 
pretreated rats. This is the dopamine response in the shell of the nucleus accumbens of 
rats after s.c. pretreatment with saline (n = 5) and β-funaltrexamine (20 mg/kg) (n = 6) 
followed 20-21 h later by i.v. infusion with saline. The volume of saline infused = 1 
mL/kg.
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The basal dopamine levels, before morphine administration, were 1.2 ± 0.3 and 
1.6 ± 0.4 nM for control and rats pretreated with β-funaltrexamine (20 mg/kg, 
s.c.), respectively (n = 6 each). For β-funaltrexamine pretreated rats, the increase 
in dopamine after morphine was significantly attenuated compared to controls 
(Figure 3.11). ANOVA showed an effect of time (F 9, 90 = 56.51, P < 0.05) and a 
β-funaltrexamine x time interaction (F 9, 90 = 13.74, P < 0.05). Post hoc analysis 
showed that controls are different from the β-funaltrexamine treated animals at 
every time point after morphine infusion (P < 0.05) (Figure 3.11). Compared to 
morphine, saline does not increase dopamine in control (n =5) and β-
Figure 3.11. β-funaltrexamine attenuates morphine-evoked dopamine release in the 
nucleus accumbens shell in rats (time course). This is the dopamine response in the 
shell of the nucleus accumbens of rats after s.c. pretreatment with saline (control) and β-
funaltrexamine (20 mg/kg) followed 24 h later by i.v. infusion with morphine (1 mg/kg) (n 
= 6 each). Arrow indicates the morphine infusion time. * indicates significant difference 
from baseline. The # shows significant difference between control and β-funaltrexamine 
(20 mg/kg), comparing individual time points after the infusion.
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funaltrexamine (20 mg/kg s.c.) (n = 6) pretreated rats (F 9, 79 = 0.33, P > 0.05, for 
the β-funaltrexamine x time interaction) (Figure 3.10). Also, a One-way ANOVA 
analysis of the morphine-evoked dopamine AUC showed that there was a 
difference between controls (n = 6) and β-funaltrexamine (n = 6) (F 1, 11 = 47.12, 
P < 0.05) (Figure 3.12).
Figure 3.12. β-funaltrexamine inhibits morphine-evoked dopamine release in the 
nucleus accumbens shell (AUC). This shows the AUC (% basal dopamine) in the 
nucleus accumbens shell after i.v. pretreatment with saline and β-funaltrexamine (20 
mg/kg) followed 20-24 h later by i.v. infusion with morphine (1 mg/kg). * shows a 
significant difference from saline controls. bfna = β-funaltrexamine.
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β-funaltrexamine attenuated ethanol-evoked mesolimbic dopamine release. 
In these experiments, rats were pretreated subcutaneously with saline (control) 
or β-funaltrexamine (20 mg/kg), followed 20-25 h by saline and ethanol (10%w/v, 
1 g/kg, i.v.). The saline i.v. treatment was equivalent to the ethanol volume, and 
all control and β-funaltrexamine pretreated animals received saline followed by 
ethanol infusions. The control (n = 8) and β-funaltrexamine groups (n = 6) had 
basal dopamine concentrations (before ethanol infusion) of 1.2 ± 0.2 and 1.0 ± 
0.2 nM respectively. For control rats, ethanol, but not saline, increased dopamine 
(~50% of baseline) (Figure 3.13 and 3.14). We determined that β-funaltrexamine 
attenuated ethanol-evoked mesolimbic dopamine release (Figure 3.14). ANOVA
Figure 3.13. β-funaltrexamine does not change the effect of saline infusion on dopamine 
release in the nucleus accumbens shell. This is the dopamine response in the shell of 
the nucleus accumbens of rats after s.c. pretreatment with saline (n = 5) and β-
funaltrexamine (20 mg/kg) (n = 6) followed 20-23 h later by i.v. infusion with saline. The 
volume of saline infused = 10 mL/kg.
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detected significance as follows: (F 7, 82 = 19.86, P < 0.05, time), (F 7, 82 = 2.67, P 
< 0.05, for the β-funaltrexamine x time interaction).
Post hoc analysis showed that compared to basals, control animals showed an 
increase in dopamine after ethanol for every time point (25 min after infusion) 
included in the analysis whereas β-funaltrexamine treated animals showed an 
increase in dopamine only in the first 2 time points (10 min after infusion) (Figure 
3.14). Compared to ethanol, saline does not cause any change in dopamine 
Figure 3.14. β-funaltrexamine attenuates ethanol-stimulated dopamine release in the 
nucleus accumbens shell. This is the dopamine response in the shell of the nucleus 
accumbens of rats after s.c. pretreatment with saline (n = 8) and β-funaltrexamine (20 
mg/kg) (n = 6) followed 24-25 h later by i.v. infusion with ethanol (1 g/kg, 10% w/v). 
Arrow indicates the ethanol infusion time. The * shows significance compared to basals 
and the # shows significant difference between control and β-funaltrexamine pretreated 
rats, comparing individual time points after the infusion.
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levels in β-funaltrexamine and control animals (n = 5 each) (Figure 3.13). There 
was no significant difference in dialysate dopamine from the NAcS after saline 
was administered intravenously to control and β-funaltrexamine (20 mg/kg, s.c.) 
pretreated rats (F 9, 69 = 1.99, P > 0.05, for the β-funaltrexamine x time 
interaction) (Figure 3.13). 
β-funaltrexamine did not alter dialysate ethanol peak and time course. The peak 
ethanol concentrations were 5.5 ± 0.8 and 5.9 ± 0.5 mM for control (n = 8) and β-
funaltrexamine (20 mg/kg) (n = 6) pretreated rats respectively, and there was no 
significant difference in the peak ethanol concentration (F 1, 13 = 0.17, P > 0.05, 
for the β-funaltrexamine x time interaction) and in the time course of ethanol (F 11, 
132 = 0.30, P > 0.05, for the β-funaltrexamine x time interaction) (Figure 3.15).
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Discussion
The hypothesis that the µ-opioid receptors play a role in the mechanism of 
ethanol-stimulated dopamine in the NAcS is supported by this data. We show 
that naltrexone, a non-selective opioid antagonist, did not affect basal dopamine 
levels (Figure 3.2), but dose-dependently attenuated morphine-evoked dopamine 
release in the NAcS (Figures 3.3 and 3.4). At doses effective in attenuating 
Figure 3.15. β-funaltrexamine does not affect the peak concentration and time course of 
ethanol in the nucleus accumbens shell. This shows the ethanol concentrations in the 
shell of the nucleus accumbens of male Long Evans rats after i.v. pretreatment with 
saline (n = 8) and β-funaltrexamine (bfna) (20 mg/kg) (n = 6) followed 24-25 h later by 
i.v. infusion with ethanol (1 g/kg, 10% w/v). Mean + SEM are shown for each point. 
Arrow indicates the ethanol infusion time.
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morphine-evoked dopamine release in the NAcS, naltrexone did not prevent 
ethanol from increasing dopamine, but instead prevented the dopamine increase 
from being prolonged (Figure 3.8). β-funaltrexamine, a selective irreversible µ-
opioid antagonist (Ward et al., 1982, 1985; Liu-Chen and Phillips, 1987; Liu-Chen 
et al., 1990, 1991), at a dose that significantly attenuated morphine-evoked 
dopamine release in the NAcS (Figures 3.11 and 3.12), also inhibited the 
prolongation of ethanol-evoked dopamine release (Figure 3.14). Neither 
naltrexone nor β-funaltrexamine affected the pharmacokinetics of ethanol in the 
brain (Figures 3.9 and 3.15). However, we detected a gradual decrease in 
dopamine levels beginning at 20 min after saline administration (Figure 3.5, 3.6 
and 3.7). Therefore, we restricted our analysis to first 20 min after ethanol and 
saline infusions. We cannot explain this gradual decrease in basal dopamine 
after naltrexone pretreatment and saline infusion. However, we do know that this 
is not due to naltrexone infusion, because naltrexone does not change basal 
dopamine levels (Figure 3.2). Notwithstanding this potential confound to the 
interpretation of our naltrexone data, we obtained a similar effect with β-
funaltrexamine on ethanol-stimulated dopamine release in the NAcS, reinforcing 
our conclusions. Together, our data support our conclusion that the µ-opioid 
receptors are involved in a delayed component of the mechanism of ethanol-
stimulated dopamine release in the NAcS of ethanol-naïve rats. 
The NAc is divided into core and shell sub-regions. We sampled from the shell in 
all rats used in our experiments. Compared to the NAc core, the NAc shell is 
more sensitive to the dopamine-stimulating effects of morphine and ethanol 
(Pontieri et al., 1995; Howard et al., 2008). There are multiple opioid receptors (µ, 
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δ, and κ), and activation of µ- and δ-opioid receptors enhances mesolimbic 
dopamine release (for review, see Herz, 1997). In order to characterize the 
specific contribution of the µ-opioid receptor in ethanol-stimulated dopamine 
release, we used morphine (selective systemic µ-opioid receptor agonist), as a 
positive control to determine the doses of naltrexone and β-funaltrexamine that 
are effective in attenuating morphine-evoked dopamine release in the NAcS 
(Figures 3.3, 3.4, 3.11 and 3.12). To our knowledge, we are the first to do a 
dose-response study involving the effect of naltrexone on morphine-evoked 
mesolimbic dopamine. We are also the first to study the effect of systemic β-
funaltrexamine on morphine-induced dopamine release in the NAc. Morphine 
increases mesolimbic dopamine release, and though morphine has been shown 
to act at the different opioid receptors (including µ- and δ-opioid receptors which 
activate mesolimbic dopamine), the morphine-evoked increase in mesolimbic 
dopamine is predominantly due to activation of the µ-opioid receptor. For 
instance, both intracerebroventricular administered β-funaltrexamine (Di Chiara 
and Imperato, 1988b) and systemic naloxone (Borg and Taylor, 1997) 
suppressed systemic morphine-evoked dopamine increase in the NAc, whereas 
systemic naltrindole, a highly selective δ-opioid antagonist, did not (Borg and 
Taylor, 1997). Moreover, µ-opioid receptor knockout mice showed attenuation in 
mesolimbic dopamine release due to experimenter-administered morphine 
(Chefer et al., 2003) whereas δ-opioid receptor knockout mice did not. In 
addition, morphine has a significantly higher (> 100 fold) affinity for the µ- relative 
to the δ-opioid receptor (Raynor et al., 1994). Thus, systemic morphine is 
predominantly acting at the µ-receptors to increase dopamine in the NAc. This 
makes morphine a good positive control. Our data shows that naltrexone 
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(Figures 3.3 and 3.4) and β-funaltrexamine (Figures 3.11 and 3.12), through 
blockade of the µ-opioid receptor, suppressed morphine-evoked dopamine 
release in the NAcS. A limitation of the naltrexone experiments is that the non-
selective nature of naltrexone makes conclusions regarding specific opioid 
receptors difficult to make. This limitation is addressed by the experiments with β-
funaltrexamine-a selective µ-opioid receptor antagonist. However, a limitation of 
the β-funaltrexamine experiments is that β-funaltrexamine also binds to the µ-δ 
opioid receptor complex (Rothman et al., 1988, 1991), and we cannot rule this 
out.
The mechanism of ethanol-evoked mesolimbic dopamine is thought to include 
ethanol-stimulated endogenous opioid release to activate the µ-opioid receptors 
(Herz, 1997; Xiao and Ye, 2008). Our data shows that naltrexone (Figure 3.8) 
and β-funaltrexamine (Figure 3.14), at doses effective in suppressing morphine-
evoked dopamine release in the NAcS (Figures 3.3, 3.4, 3.11, and 3.12), 
attenuated ethanol-induced dopamine release. To the best of our knowledge, we 
are the first to study the effect of systemic β-funaltrexamine on ethanol-induced 
dopamine release in the NAc.
Our naltrexone data (Figure 3.8) supports another publication that shows that 
naltrexone attenuates ethanol-stimulated mesolimbic dopamine release. 
Benjamin et al. (1993) reported that naltrexone reverses ethanol-induced 
dopamine release in the NAc in awake, freely moving Long Evans rats. However, 
some limitations inherent in the experimental design by Benjamin et al. (1993) 
include continuous local delivery into the NAc of a very high dose of ethanol (> 
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800 mM) throughout the duration of the experiment (200 min). We reached the 
same conclusions reached by Benjamin et al. (1993), though we employed 
systemic administration of ethanol, presenting a more comprehensive and 
realistic view of the effect of naltrexone on acute ethanol-evoked mesolimbic 
dopamine release.
Our data shows that the attenuating effects on the ethanol-stimulated dopamine 
response of both naltrexone and β-funaltrexamine are not immediate but delayed 
(Figures 3.8 and 3.14). We were able to detect this delay in the µ-opioid receptor-
mediated component of the ethanol-evoked dopamine response because in our 
experiments, we analyzed changes in dopamine in the NAc over relatively short 
time periods (5 min).This presents a better time resolution of the changes in 
dopamine compared to other similar microdialysis studies (20 min) that have 
attempted to characterize the role of the opioid receptors in the mechanism of 
ethanol-stimulated mesolimbic dopamine release (Acquas et al., 1993; Benjamin 
et al., 1993; Tanda and Di Chiara, 1998).
There are other studies that show that the µ-opioid receptor component in the 
mechanism of ethanol-stimulated dopamine release is delayed. Naloxonazine, an 
irreversible selective µ1-opioid receptor subtype antagonist, blocks morphine and 
ethanol-mediated dopamine release in the NAc (Tanda and Di Chiara, 1998) in 
freely-moving male Sprague-Dawley rats. After careful study of the data in the 
paper by Tanda and Di Chiara (1998), we realize that, similar to our results, the 
effect of µ1-opioid receptor blockade on the dopamine response due to ethanol 
(0.25 and 0.5 g/kg i.p.) was delayed (see Tanda and Di Chiara, 1998). In 
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addition, we published our findings of the effect of ethanol on dopamine release 
in the ventral striatum of C57BL/6 mice (Job et al., 2007), and determined that 
the µ-opioid receptor is involved in this mechanism. However, the data (see Job 
et al., 2007) shows that µ-opioid knockout males on the mixed genetic 
background (C57BL/6J-129SvEv) showed increases in dopamine evoked by 2
g/kg ethanol i.p. injection (similar to their wildtype controls), but this dopamine 
increase returned to baseline more rapidly compared with controls. It is important 
to note that µ-opioid knockout females (unlike the males) on the mixed genetic 
background (C57BL/6J- 129SvEv), and µ-opioid knockouts on the congenic 
C57BL/6J background, showed a complete blockade of ethanol-stimulated 
dopamine release (Job et al., 2007). 
Thus, our present data together with previous findings (Benjamin et al., 1993; 
Tanda and Di Chiara, 1998; Job et al., 2007) all reinforce the idea that the µ-
opioid receptor is involved in a delayed component of the ethanol-stimulated 
mesolimbic dopamine response. We do not know why there is a delay in the 
opioid effect on ethanol-induced mesolimbic dopamine response (Figures 3.8
and 3.14), and further research needs to be done clarify this. However, ethanol 
can increase dopamine through multiple non-opioid mechanisms, and these 
other mechanisms may be involved in the early component of the dopamine 
response. 
In conclusion, we have presented data showing that the µ-opioid receptors are 
involved in ethanol-stimulated dopamine in the NAcS of ethanol-naïve rats. 
Furthermore, the µ-opioid receptors are involved in a delayed component of the 
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mechanism of ethanol-stimulated dopamine release in the NAcS of ethanol-naïve 
rats. It is important to add that our conclusions are limited to the NAcS as we did 
not determine the effects of µ-opioid receptor blockade on the mechanism of 
ethanol-evoked dopamine release in other regions of the NAc.
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Chapter 4. Summary and Conclusions
The overall hypothesis for the dissertation is that the µ-opioid receptors play a 
role in the mechanism of ethanol-stimulated mesolimbic dopamine release. The 
experimental techniques included jugular catheterizations and stereotaxic 
surgeries that were done to prepare the rats for intravenous drug administration 
and microdialysis, respectively. Microdialysis sampling time was 5 min, and 
dialysate samples were analyzed for ethanol and dopamine by GC and HPLC, 
respectively. We did histological analysis to determine that the dialysis probes 
had been placed into the nucleus accumbens shell (NAcS). The experiments 
were designed to determine the effect of µ-opioid antagonists on morphine- and 
ethanol-stimulated mesolimbic dopamine release. We did two sets of 
experiments - the naltrexone and the β-funaltrexamine experiments. There are 
no literature reports looking at naltrexone dose-response effect on morphine-
induced dopamine release. In addition, the only record in the literature for the 
effects of naltrexone on acute ethanol-induced mesolimbic dopamine release 
involved a local administration of ethanol into the NAc (Benjamin et al., 1993). 
We present a more comprehensive design and more thorough analysis of 
naltrexone using systemic ethanol administration. A previous experiment had 
looked at the effect of intracerebroventricularly administered β-funaltrexamine on 
morphine-induced dopamine release (Di Chiara and Imperato, 1988b), but we 
are the first to report on the effect of systemic β-funaltrexamine on morphine-
induced dopamine release in the NAcS. We are also the first to report on the 
effect of systemic β-funaltrexamine on ethanol-induced dopamine release in the 
NAcS.
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For the naltrexone experiments, we did a dose-response study in order to 
determine naltrexone doses that were effective in attenuating morphine-induced 
dopamine release in the NAcS. This is a positive control experiment, and 
morphine was used because it is a relatively selective µ-opioid agonist. 
Naltrexone is a non-selective opioid antagonist, and we tried to determine a dose 
that achieved a significant blockade of the µ-opioid receptors involved in 
mesolimbic dopamine release. We found that morphine, via activation of the µ-
opioid receptors, increases dopamine in the NAcS. This is supported by evidence 
in the literature showing that the µ-opioid receptors play a role in morphine-
evoked mesolimbic dopamine release. Furthermore, we determined that 
naltrexone dose-dependently attenuates this morphine-evoked dopamine 
release. We inferred that at the doses effective in suppressing morphine-evoked 
dopamine release, naltrexone achieves a significant blockade of the µ-opioid 
receptors that are involved in mesolimbic dopamine release.
Another set of experiments was done to determine if naltrexone, at doses 
effective in suppressing morphine-evoked dopamine release, suppresses 
ethanol-stimulated dopamine release in the NAcS. We determined that 
naltrexone was effective in attenuating ethanol-stimulated dopamine release in 
the NAcS. However, we noticed that this attenuation was not immediate. Further 
analysis found that the ethanol-induced dopamine response consisted of two 
components – an early non-opioid component that was not responsive to 
naltrexone, and a delayed opioid component that was responsive to naltrexone. 
We also noticed that there was no dose-dependent effect of increasing the 
naltrexone dose. We concluded that naltrexone attenuates ethanol-stimulated 
dopamine release, though this effect is delayed. We concluded that the µ-opioid 
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receptors are involved in a delayed component of ethanol-stimulated dopamine 
release in the NAcS in naïve rats.
As we mentioned in the previous paragraph, there is no dose-dependent effect of 
naltrexone on ethanol-stimulated dopamine release beyond a naltrexone dose of 
0.3 mg/kg. Of the opioid receptors, naltrexone has the highest affinity at µ-opioid 
receptors, and increasing the dose therefore is presumed to cause additional 
blockade of other opioid receptors including the δ-opioid receptor. However, this 
did not cause an additional inhibition of ethanol-stimulated dopamine release. We 
speculate that δ-opioid receptors contribute to ethanol-stimulated dopamine 
release via interaction with the µ-opioid receptors (see more details in section of
general introduction regarding µ- and δ-opioid receptor interactions in the 
mechanism of mesolimbic dopamine release). Therefore when significant 
populations of the µ-opioid receptors that are involved in mesolimbic dopamine 
release have been blocked, they are not available to interact with δ-opioid 
receptors, and activation of additional δ-opioid receptors may not lead to an 
increase in mesolimbic dopamine release. A limitation of this experiment is that 
even though we used naltrexone doses < 1 mg/kg, we cannot rule out the 
involvement of other opioid receptors in the effects of naltrexone. We decided to 
use a more selective µ-opioid receptor antagonist as a tool to further strengthen 
our conclusions.
There is extensive evidence that β-funaltrexamine is a selective irreversible µ-
opioid receptor antagonist (Ward et al., 1982, 1985; Liu-Chen and Phillips, 1987; 
Liu-Chen et al., 1990, 1991). For the β-funaltrexamine experiments, like the 
naltrexone experiments, we determined a dose of β-funaltrexamine that was 
effective in significantly attenuating the morphine-evoked dopamine release in 
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the nucleus accumbens shell (positive control). The effective dose of β-
funaltrexamine is thought to achieve a significant blockade of the µ-opioid 
receptors in order to attenuate morphine-induced dopamine release. Our data 
show that β-funaltrexamine, at doses effective in suppressing morphine-evoked 
dopamine release in the nucleus accumbens shell, attenuated ethanol-induced 
dopamine release. The results from the β-funaltrexamine experiments reinforce 
our conclusions from the naltrexone experiments. We have confirmed that the µ-
opioid receptors play a role in the mechanism of ethanol-stimulated dopamine 
release. However, again, the opioid-driven component of the ethanol-stimulated 
dopamine response is delayed.
Our results support the overall hypothesis of this dissertation. However, we have 
been able to uncover for the first time a delay in the µ-opioid effects. We were 
able to detect this delay in the µ-opioid receptor-mediated component of the 
ethanol-evoked dopamine response because in our experiments, we analyzed 
changes in dopamine in the NAc over relatively short time periods (5 min).This 
presents a better time resolution of the changes in dopamine compared to other 
similar microdialysis studies (20 min) that attempt to characterize the role of the 
opioid receptors in the mechanism of ethanol-stimulated mesolimbic dopamine 
release (Acquas et al., 1993; Benjamin et al., 1993; Tanda and Di Chiara, 1998). 
This is a significant contribution to the field. However, this finding raises more 
questions about the opioid-driven mechanism of ethanol-stimulated dopamine 
release. For example: Why is the µ-opioid effect delayed? What non-opioid 
mechanisms constitute the early component of the dopamine response? How 
may this finding be related to ethanol reinforcement and even the 
pharmacotherapy of ethanol dependence?
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Why is the µ-opioid effect delayed? We propose that two broad mechanisms may 
be involved in the opioid effect on ethanol-stimulated dopamine. The opioids 
could be prolonging the dopamine release by either increasing the dopamine 
release, or by preventing its decrease. Since opioids are known to be inhibitory, it 
is likely that the prominent mechanism here will be a prevention of the decrease 
in dopamine. This can be done by opioid-mediated inhibition of mechanisms that 
would otherwise have decreased the dopamine release. Such inhibitory 
mechanisms could be exerted by GABA or glycine. Apart from these, it is 
tempting to speculate that the opioids may have some inhibitory effect at 
monoamine transporters such as the dopamine transporter, but there is no 
evidence of this in the literature. Thus, we are left with the idea that opioids inhibit 
GABAergic neurons, preventing the decrease in dopamine release, in order to 
prolong the effect of ethanol-stimulated dopamine release. However, the 
question as to the mechanism still remains.
More acceptable ideas about the opioid mechanisms of ethanol-stimulated 
mesolimbic dopamine release have to do with ethanol-stimulated release of the 
endogenous opioid peptides. It has been proposed that one of the mechanisms 
by which ethanol stimulates dopamine release in the NAcS is by increasing β-
endorphin release into the VTA. Dopamine neurons in the VTA receive inhibitory 
inputs from GABAergic afferents and interneurons, and the released β-endorphin 
is then proposed to act on µ-opioid receptors on the GABAergic neurons, 
inhibiting them, and thereby increasing VTA dopaminergic activity via 
disinhibition mechanisms (Herz, 1997). In the literature, however, there is no 
direct evidence showing that β-endorphin fibers from the hypothalamus project to 
the VTA (Khatchaturian and Watson, 1982). Also, evidence seems to suggest 
that the NAc is more sensitive than the VTA to the effects of β-endorphin
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(Ableiter and Schulz, 1992), and this is buttressed by the observation that there
are direct β-endorphin projections from the hypothalamus to the NAc and not the 
VTA (Khatchaturian and Watson, 1982). However, in the NAc, β-endorphin 
release seems to be a consequence and not the cause of dopamine release
(Roth-Deri et al., 2003). One possible explanation is that β-endorphin is released 
in the VTA (Jarjour and Gianoulakis, 2006) or at other neuroanatomical 
structures and diffuses to access sites in the VTA. This may explain the delay in 
the opioid effects (see Figure 2.4). We know that β-endorphin is released by 
ethanol and involved in ethanol reinforcement. We are not very convinced,
however, that it plays a role in the mechanism of ethanol-stimulated dopamine 
release. More investigations need to be done to clarify this.
To us, a more reasonable idea seems to be the involvement of enkephalins in
the mechanism of ethanol-stimulated dopamine release. There are many 
instances in the literature that show that enkephalinergic neurons interact very 
extensively with the mesolimbic dopaminergic neurons. For instance, 
enkephalinergic cell bodies are found in the VTA (Finley et al., 1981b; Harlan et 
al., 1987), and enkephalinergic neurons synapse on the dopaminergic neurons
and GABAergic interneurons in the VTA (Sesack and Pickel, 1992, 1995). Also, 
enkephalins have also been shown to be involved in dopaminergic tone, since
inhibiting the metabolism of enkephalin in the ventral tegmental area leads to an 
increase in dopamine release in the NAc (Daugé et al., 1992). Enkephalins have 
also been shown to be co-localized in GABAergic neurons in the VTA and NAc
(Sesack and Pickel, 1992, 1995; Kalivas et al., 1993; Curran and Watson, 1995).
Furthermore, enkephalins have a high affinity and efficacy at the µ-opioid 
receptors (Raynor et al., 1994).
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We propose that in the fast non-opioid component of the dopamine response, 
ethanol directly activates the dopaminergic neurons to increase dopamine. Also 
within this early component of the dopamine response, ethanol recruits some 
other non-opioid mechanisms such as serotonergic, acetylcholine, glycinergic
and GABA. Ethanol also releases enkephalin (Marinelli et al., 2005). However, 
we propose that, as with other neuropeptides, enkephalin is not released at the 
synaptic sites, and has to diffuse some distance to access its postsynaptic target 
sites (see figure 2.4). This may account for the delay in the opioid effect. 
Enkephalin then inhibits the inhibitory GABA inputs (from afferents or 
interneurons), leading to an increase in dopaminergic neuron firing and increase 
in accumbal dopamine release. 
We looked at the effect of µ-opioid receptors, and more likely candidates are the 
very highly selective endomorphins. Endomorphins project to the ventral 
tegmental area and the nucleus accumbens, and increase mesolimbic dopamine. 
However, in literature, the involvement of the endomorphins in the mechanism of 
ethanol-stimulated mesolimbic dopamine has not been determined. More 
research needs to be done to find out if endomorphins play a role in this 
mechanism. 
How may the finding that the µ-opioid component of ethanol-stimulated dopamine 
response is delayed be related to ethanol reinforcement and even the 
pharmacotherapy of ethanol dependence? Naltrexone is thought to exert its 
suppressive effect on ethanol reinforcement through blockade of the µ-opioid 
receptor. However, there is evidence that naltrexone is not effective in all 
alcoholic subjects. Many drugs that have been shown to be effective in 
suppressing ethanol reinforcement have also been shown to suppress ethanol-
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stimulated mesolimbic dopamine release. As we show in our data, naltrexone 
does not suppress an early component of ethanol-evoked dopamine response. 
Therefore, it is important to determine the importance of this early component. 
Perhaps more effective therapies would combine naltrexone with a drug that 
blocks the early component of the ethanol-induced dopamine response. Taking a 
closer look at the non-opioid mechanisms of ethanol stimulated dopamine 
release, therefore, may be important. For instance, the possibility of combining 
naltrexone with ion channel-type drugs, 5-HT3 receptor antagonists, cannabinoid 
receptor antagonists, nicotinic acetylcholine receptor antagonists, GABAergic 
agonists, etc. may offer more advantage. This seems to hold promise as 
naltrexone when given in combination with the 5-HT3 antagonist: ICS 205-930 
was significantly more efficacious in suppressing ethanol intake in comparison 
with naltrexone administered alone (Mhatre et al., 2004). Also, combined low 
dose treatment with naltrexone and SR 141716 (a cannabinoid receptor 
antagonist) synergistically reduces the motivation to consume alcohol in rats 
(Gallate et al., 2004).
The present studies raise several questions. For instance, naltrexone is used in 
ethanol-experienced subjects, whereas our experiments were carried out in 
ethanol naïve subjects. Is it possible that the opioids act differently in ethanol-
experienced versus ethanol-naïve subjects with regards to their input into the 
mechanism of ethanol-stimulated mesolimbic dopamine release? Also, 
microdialysis experiments done to determine ethanol-stimulated opioid release 
tell us that ethanol increases opioid peptides, but they do not give us any 
information regarding the involvement of such an opioid in the mechanism of 
ethanol-stimulated dopamine release. An experiment that can actually confirm 
that these opioid peptides are involved in the dopamine response due to ethanol
117
needs to be done. The following experiments represent future directions in this 
area of research:
(1) Determine if the opioid-driven component of the ethanol-stimulated 
mesolimbic dopamine response shifts to the early phase in ethanol-experienced 
rats as opposed to naïve rats. Here, male Long Evans rats are given access to 
ethanol over a determined time period to make them experienced. Afterwards, 
the effect of naltrexone on ethanol-stimulated dopamine release is determined.
(2) Determine which endogenous opioid(s) contributes to the mechanism of 
ethanol-stimulated mesolimbic dopamine release. These experiments will include 
microinjection techniques, with rats intracerebroventricularly (i.c.v.) infused with 
antisera to β-endorphin, met- and leu-enkephalin, endomorphin-1 and -2, 
dynorphin and [D-Ala2] deltorphin I, and determine the effect of this on the 
mechanism of ethanol-stimulated dopamine release in the nucleus accumbens 
shell. Positive control experiments will involve i.c.v. infusing the rats with the 
antisera followed by i.c.v. administration of the opioid peptide and determining 
mesolimbic dopamine release.
We set out to determine the contribution of the µ-opioid receptors to the 
mechanism of ethanol-stimulated mesolimbic dopamine release. Our results tell 
us that the µ-opioid receptors play a role in a delayed component of the 
mechanism of ethanol-evoked mesolimbic dopamine response. Our results have 
shown for the first time that the ethanol-mediated dopamine response consists of 
distinct components. Our results have also identified the µ-opioid-driven 
component of the ethanol-stimulated dopamine response. This is a new finding 
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that has a potential of significantly advancing the knowledge in the mechanism of 
ethanol reinforcement and the management of ethanol dependence.
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